Document:

Commitment Letter

 Exhibit 10.2 

EXECUTION VERSION 
  

					
	 J.P. MORGAN SECURITIES INC.

JPMORGAN CHASE BANK, N.A.
 270 Park
Avenue
 New York, New York 10017
	 	 BARCLAYS BANK PLC
 BARCLAYS
CAPITAL
 745 Seventh Avenue
 New York,
New York 10019
	 	 UBS SECURITIES LLC
 299 Park
Avenue
 New York, NY 10171
 UBS LOAN
FINANCE LLC
 677 Washington Boulevard

Stamford, CT 06901

June 9,
2010                                 

Allscripts-Misys Healthcare Solutions, Inc. 

222 Merchandise Mart, Suite 2024 
 Chicago, IL
60654 
 Attention:         William J. Davis, Chief Financial Officer 

Allscripts-Misys Healthcare Solutions, Inc. 

Senior Secured Credit Facilities 

Commitment Letter 
 Ladies
and Gentlemen: 
 You have advised J.P. Morgan Securities Inc. (“JPMorgan”), JPMorgan Chase Bank, N.A.
(“JPMorgan Chase Bank”), Barclays Bank PLC (“Barclays Bank”), Barclays Capital, the investment banking division of Barclays Bank (“Barclays Capital”), UBS Securities LLC (“UBSS”)
and UBS Loan Finance LLC (“UBS” and together with JPMorgan, JPMorgan Chase Bank, Barclays Bank, Barclays Capital and UBSS, the “Commitment Parties”) that Allscripts-Misys Healthcare Solutions, Inc. (the
“Borrower”) intends to enter into the Transactions described in the introductory paragraph of Exhibit A hereto. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Summary of Terms
and Conditions attached hereto as Exhibit A (the “Term Sheet”). The sources and uses of funding for the Transactions are described in the Sources and Uses Table (the “Table”) attached hereto as Schedule I.

 JPMorgan, Barclays Capital and UBSS are pleased to advise you that they are willing to act as joint lead arrangers and joint
bookrunners for the Facilities. Furthermore, (i) JPMorgan Chase Bank is pleased to advise you of its several commitment to provide 55% of the aggregate amount of each of the Facilities, (ii) Barclays Bank is pleased to advise you of its
several commitment to provide 30% of the aggregate amount of each of the Facilities and (iii) UBS is pleased to advise you of its several commitment to provide 15% of the aggregate amount of each of the Facilities (JPMorgan Chase Bank,

 2 
  

 
Barclays Bank and UBS, together, the “Initial Lenders”). This Commitment Letter, the Term Sheet and the Table (collectively, the “Commitment Letter”) set forth
the terms and conditions on and subject to which the Initial Lenders are willing to make their commitments. 
 It is agreed that
JPMorgan, Barclays Capital and UBSS will act as joint lead arrangers and joint bookrunners in respect of the Facilities (in such capacities, the “Arrangers”) and that JPMorgan will have “left” placement in any marketing
materials or other documentation used in connection with the Facilities. It is further agreed that JPMorgan Chase Bank will act as the sole administrative agent in respect of the Facilities. You agree that, as a condition to the commitments and
agreements hereunder, no other agents, co-agents, bookrunners or arrangers will be appointed, no other titles will be awarded and no compensation will be paid in connection with the Facilities (in each case other than that expressly contemplated by
the Term Sheet and the Fee Letter referred to below) unless you and we shall so agree. 
 You understand that the Facilities
will be syndicated and you agree to actively assist the Arrangers in completing timely syndications reasonably satisfactory to the Arrangers and you. We intend to commence syndication efforts promptly, and you agree to actively assist us in
completing a syndication reasonably satisfactory to us and you. Such assistance shall include (a) your using commercially reasonable efforts to ensure that the syndication efforts benefit materially from your existing banking relationships,
(b) direct contact between your senior management and the proposed Lenders and your using commercially reasonable efforts to ensure direct contact between your advisors and the proposed Lenders at mutually convenient times and locations,
(c) as set forth in the next paragraph, assistance from you in the preparation of materials to be used in connection with the syndication (collectively, with the Term Sheet, the “Information Materials”) and (d) the
hosting, with us and your senior management, of one or, if mutually agreed, additional meetings of prospective Lenders at mutually convenient times and locations. 

You will assist us in preparing Information Materials, including Confidential Information Memoranda, for distribution to prospective
Lenders. If requested, you also will assist us in preparing an additional version of the Information Materials (the “Public-Side Version”) to be used by prospective Lenders’ public-side employees and representatives
(“Public-Siders”) who do not wish to receive material non-public information (within the meaning of United States federal securities laws) with respect to the Borrower, the Target, their respective affiliates and any of their
respective securities (“MNPI”) and who may be engaged in investment and other market related activities with respect to any such entity’s securities or loans. Before distribution of any Information Materials, you agree to
execute and deliver to us (i) a letter in which you authorize distribution of the Information Materials to a prospective Lender’s employees willing to receive MNPI (“Private-Siders”) and (ii) a separate letter in
which you authorize distribution of the Public-Side Version to Public-Siders and represent that no MNPI is contained therein. You also acknowledge that Commitment Party Public-Siders who are publishing debt analysts may participate in any meetings
held pursuant to clause (d) of the preceding paragraph to the extent that such meeting is open to any Public-Siders; provided that such analysts shall not publish any information obtained from such meetings at any time in violation of any
confidentiality agreement between you and the relevant Commitment Party Public-Sider. 
 The Borrower agrees that the following
documents may be distributed to both Private-Siders and Public-Siders, unless the Borrower advises the Arrangers in writing (including by email) within a reasonable time prior to their intended distribution that such materials should be distributed
only to Private-Siders: (a) administrative materials prepared by the Commitment Parties for prospective Lenders (such as a lender meeting invitation, lender allocation, if any, and funding and closing memoranda), (b) notification of
changes in the terms of the Facilities and (c) other materials designated by the Borrower for all prospective Lenders after the initial distribution of Information Materials. If you advise us that any of the foregoing should be distributed only
to Private-Siders, then Public-Siders will 

 3 
  

 
not receive such materials without further discussions with you. The Borrower hereby authorizes the Commitment Parties to distribute draft and final definitive documentation with respect to the
Facilities (other than any such documentation identified by the Borrower in writing (including by email) within a reasonable time prior to the intended distribution for distribution solely to Private-Siders) to Private-Siders and Public-Siders.

 JPMorgan, Barclays Capital and UBSS, in their capacity as Arrangers, will manage, in consultation with you, all aspects of
the syndication, including decisions as to the selection of institutions to be approached and when they will be approached, when their commitments will be accepted, which institutions will participate, the allocation of the commitments among the
Lenders and, subject to the terms of the Fee Letter, the amount and distribution of fees among the Lenders. In their capacity as Arrangers of the Facilities, JPMorgan, Barclays Capital and UBSS will have no responsibility other than to arrange the
syndication as set forth herein and in no event shall be subject to any fiduciary or other implied duties. Additionally, the Borrower acknowledges and agrees that, as Arrangers, JPMorgan, Barclays Capital and UBSS are not advising the Borrower as to
any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Borrower shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the
transactions contemplated hereby, and the Arrangers shall have no responsibility or liability to the Borrower with respect thereto. 

To assist us in our syndication efforts, you agree promptly to prepare and provide to us all information with respect to the Borrower and
its subsidiaries and the Transactions, including all financial information and projections (the “Projections”), as we may reasonably request in connection with the arrangement and syndication of the Facilities. You hereby
represent and covenant that (a) all written information and all oral communication made in Lender meetings and due diligence sessions held in connection with the syndication of the Facilities (other than the Projections and information of a
general economic or industry-specific nature) (the “Information”) that has been or will be made available to us by you or any of your representatives is or will be, taken as a whole, when furnished, complete and correct in all
material respects and does not or will not, taken as a whole, when furnished, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein not materially misleading in
light of the circumstances under which such statements are made (after giving effect to all supplements thereto) and (b) the Projections that have been or will be made available to us by you or any of your representatives have been or will be
prepared in good faith based upon assumptions that you reasonably believe to have been reasonable at the time made and at the time such Projections are made available to the Arrangers (it being understood that any such Projections are subject to
significant uncertainties and contingencies, many of which are beyond your control, and that no assurance can be given that such Projections will be realized and that actual results may differ from such Projections and that such differences may be
material). You understand that in arranging and syndicating the Facilities we may use and rely on the Information and Projections without independent verification thereof. 

If any Initial Lender becomes a Defaulting Lender (as defined below), you may, at your sole expense and effort, upon notice to such
Initial Lender and the Arrangers, require such Initial Lender to assign and delegate, without recourse, all of its interests, rights and obligations under this Commitment Letter to an assignee selected by you in consultation with the Arrangers (a
“Replacement Lender”) that shall assume such obligations (which assignee may be another Initial Lender, if such other Initial Lender accepts such assignment). The Arrangers agree to use their commercially reasonable efforts to
assist you in identifying a Replacement Lender and effecting any such assignment and delegation (it being understood that such efforts shall not be deemed to require the Arrangers to cause any of their affiliates to agree to become the Replacement
Lender). It is understood and agreed that any such assignment and delegation shall not reduce or otherwise affect the commitments in respect of the Facilities of the other 

 4 
  

 
Initial Lenders. For purposes of the foregoing, “Defaulting Lender” shall mean shall mean any Initial Lender that (a) becomes (or is controlled by any person or entity that
is) subject to any bankruptcy, insolvency, receivership, conservatorship or other similar proceeding, (b) has (or is controlled by any person or entity that has) become a “defaulting” lender generally in credit agreements to which it
is a party (other than actions taken in good faith to exercise or preserve its rights and remedies as a lender) or (c) refuses to execute (after reasonable written notice to such Initial Lender) or, in your reasonable judgment following
consultation with the applicable Initial Lender and the Arrangers, materially delays in executing, the definitive credit documentation with respect to the Facilities that has been fully negotiated between you and the Commitment Parties in good faith
(the “Credit Documentation”). Notwithstanding the foregoing, no Initial Lender shall be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in such Initial Lender or a parent company thereof
by a governmental authority or an instrumentality thereof. 
 As consideration for the commitments and agreements of the
Commitment Parties hereunder, you agree to cause to be paid the nonrefundable fees described in the Fee Letter dated the date hereof and delivered herewith (the “Fee Letter”). 

Each Commitment Party’s commitments and agreements hereunder are subject to (a) since May 31, 2009, there not having
occurred any Borrower Material Adverse Effect (as defined below), (b) such Commitment Party’s reasonable satisfaction that until the earlier of (i) the completion of a Successful Syndication (as hereinafter defined) and (ii) the
date that is 60 days following the initial funding of the Facilities, there shall be (or with regards to any portion of such period occurring after the Closing Date shall reasonably be expected to be) no competing offering, placement or arrangement
of any debt securities or bank financing by or on behalf of the Borrower or any of its subsidiaries (including any new subsidiaries to be formed or acquired in connection with the Transactions), (c) the Arrangers’ having been afforded a
period of not less than 45 days following the execution and delivery of this Commitment Letter to syndicate the Facilities, provided that such minimum period shall be extended in case you execute any cure rights pursuant to clause
(ii) of clause (f) of this paragraph by the time period from the date written notice is given by the Commitment Parties of noncompliance through the date such noncompliance is cured, (d) the closing of the Facilities on or before
December 9, 2010, (e) compliance by you in all material respects with your agreements in clauses (a), (b), (c) and (d) of the fourth paragraph of this Commitment Letter, other than to the extent (i) noncompliance therewith
has not materially impeded the syndication of the Facilities or (ii) you shall have cured such noncompliance within 5 business days of having received written notice from the Commitment Parties of such noncompliance (it being agreed that the
Commitment Parties shall give you prompt written notice of any such noncompliance); and (f) the other conditions expressly set forth in the Term Sheet. “Borrower Material Adverse Effect” means any event, occurrence, fact,
condition, effect, change or development that, individually or when taken together with all other events, occurrences, facts, conditions, effects, changes or developments, is, or is reasonably expected to be, materially adverse to the business,
assets, liabilities (contingent or otherwise), financial condition or results of operations of the Borrower and its Subsidiaries, taken as a whole; provided, however, that none of the following shall constitute, and no event, effect,
change or development to the extent resulting from any of the following, shall constitute or be taken into account in determining whether there has been a “Borrower Material Adverse Effect”: (i) factors affecting the national or world
economy or financial, banking, credit, securities or commodities markets, taken as a whole, except to the extent the Borrower and its subsidiaries are adversely affected in a disproportionate manner as compared to other comparable companies in the
industry in which the Borrower and its subsidiaries operate; (ii) conditions generally affecting the industries in which the Borrower or its subsidiaries operate, except to the extent the Borrower and its subsidiaries are adversely affected in
a disproportionate manner as compared to other comparable companies in the industry in which the Borrower and its subsidiaries operate; (iii) factors resulting from or arising out of the announcement of the Merger Agreement, the Misys Agreement
or the transactions contemplated thereby 

 5 
  

 
(including any shareholder or derivative litigation arising from or relating to the Merger Agreement, the Misys Agreement or the transactions contemplated thereby) or the performance of the
Merger Agreement or the Misys Agreement; (iv) any circumstances relating to the loss in whole or in part of any business relationship with any customer or client of the Borrower or any of its subsidiaries set forth in Section 9.1(A) of the
Parent Disclosure Letter, other than as a result of the valid termination by a customer or client of any written contract due to the breach by the Borrower or any of its subsidiaries of its obligations under any such written contract to license
material intellectual property rights owned by the Borrower or any of its subsidiaries or perform material services related to such licenses required to be licensed or performed, respectively, under such written contract; (v) any failure by the
Borrower to meet any analysts’ revenue or earnings projections or Borrower guidance, in and of themselves, or any failure by the Borrower to meet any of the Borrower’s internal or published revenue or earnings projections or forecasts, in
and of themselves, or any decline in the trading price or trading volume of the common stock of the Borrower, in and of themselves (it being understood that any event, occurrence, fact, condition, effect, change or development giving rise to any
such failure or decline, other than an event, occurrence, fact, condition, effect, change or development set forth in clauses (i) through (iv) above or clauses (vi) through (viii) below, may be deemed to constitute, and may be
taken into account in determining whether there has been, or is reasonably expected to be, a Borrower Material Adverse Effect); (vi) any effect resulting from changes in laws or accounting principles, in each case, after the date hereof;
(vii) any effect resulting from any outbreak or escalation of hostilities, the declaration of a national emergency or war, or the occurrence of any act of terrorism; or (viii) any increase in the cost of or decrease in the availability of
financing to the Borrower or its subsidiaries with respect to the Share Repurchases. “Successful Syndication” means that JPMorgan Chase Bank shall hold no more than $60,000,000 of the aggregate commitment amount under the
Facilities, Barclays Bank shall hold no more than $50,000,000 of the aggregate commitment amount under the Facilities and UBS shall hold no more than $40,000,000 of the aggregate commitment amount under the Facilities. 

You agree (a) to indemnify and hold harmless the Commitment Parties, their affiliates and their respective directors, employees,
advisors, and agents (each, an “indemnified person”) from and against any and all losses, claims, damages and liabilities to which any such indemnified person may become subject arising out of or in connection with this Commitment
Letter, the Fee Letter, the Facilities, the use of the proceeds thereof, the Transactions or any related transaction or any claim, litigation, investigation or proceeding relating to any of the foregoing, regardless of whether any indemnified person
is a party thereto or whether brought by the Company, the Guarantors (as defined in the Term Sheet), any of their respective affiliates or any other person or entity, and to reimburse each indemnified person upon demand for any legal or other
expenses incurred in connection with investigating or defending any of the foregoing, provided that the foregoing indemnity will not, as to any indemnified person, apply to losses, claims, damages, liabilities or related expenses to the
extent they are found by a final, non-appealable judgment of a court to arise from (i) the willful misconduct or gross negligence of such indemnified person or any of its affiliates or its or their respective officers, directors, employees or
agents or (ii) a material breach by the relevant indemnified person of the express contractual obligations of such indemnified person under this Commitment Letter or the Credit Documentation pursuant to a claim made by the Borrower, and
(b) to reimburse each Commitment Party and its affiliates on demand for all out-of-pocket expenses (including due diligence expenses, syndication expenses, consultant’s fees and expenses, travel expenses, and reasonable fees, charges and
disbursements of counsel) incurred in connection with the Facilities and any related documentation (including this Commitment Letter, the Fee Letter and the Credit Documentation) or the administration, amendment, modification or waiver thereof. No
indemnified person shall be liable for any damages arising from the use by others of Information or other materials obtained through electronic, telecommunications or other information transmission systems, except to the extent such damages are
found by a final, non-appealable judgment of a court to arise from the gross negligence or willful misconduct of such indemnified person or any of its affiliates or its or their respective officers, directors, employees or agents. In addition, no
indemnified person shall be liable for 

 6 
  

 
any special, indirect, consequential or punitive damages in connection with this Commitment Letter, the Fee Letter, the Facilities, the use of the proceeds thereof, the Transactions or any
related transaction. 
 You acknowledge that each Commitment Party and its affiliates (the term “Commitment
Party” as used below in this paragraph being understood to include such affiliates) may be providing debt financing, equity capital or other services (including financial advisory services) to other companies in respect of which you may have
conflicting interests regarding the transactions described herein and otherwise. No Commitment Party will use confidential information obtained from you by virtue of the transactions contemplated hereby or its other relationships with you in
connection with the performance by such Commitment Party of services for other companies, and no Commitment Party will furnish any such information to other companies. You also acknowledge that no Commitment Party has any obligation to use in
connection with the transactions contemplated hereby, or to furnish to you, confidential information obtained from other companies. You further acknowledge that each Arranger is a full service securities firm and each Arranger may from time to time
effect transactions, for its own or its affiliates’ account or the account of customers, and hold positions in loans, securities or options on loans or securities of the Borrower and its affiliates and of other companies that may be the subject
of the transactions contemplated by this Commitment Letter. You waive, to the fullest extent permitted by law, any claims you may have against each Commitment Party for breach of fiduciary duty or alleged breach of fiduciary duty, in each case, in
connection with the syndication of the Facilities, and agree that no Commitment Party will have any liability (whether direct or indirect) to you in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on your
behalf, including your stockholders, employees or creditors, in each case, in connection with the syndication of the Facilities. 

Each Commitment Party may employ the services of its affiliates in providing certain services hereunder and, in connection with the
provision of such services, may exchange with such affiliates, subject to the confidentiality restrictions set forth herein, information concerning you and the other companies that may be the subject of the transactions contemplated by this
Commitment Letter, and, to the extent so employed, such affiliates shall be entitled to the benefits afforded such Commitment Party hereunder. 

This Commitment Letter shall not be assignable (a) by you without the prior written consent of each Commitment Party (and prior to
the Misys Closing (as defined below), the approval of the Audit Committee of the Borrower’s Board of Directors) or (b) by any Commitment Party without the prior written consent of each Arranger and you (which consent, in the case of the
Borrower prior to the Misys Closing, shall be approved by the Audit Committee of the Borrower’s Board of Directors) and any purported assignment without such consent shall be null and void, is intended to be solely for the benefit of the
parties hereto and is not intended to confer any benefits upon, or create any rights in favor of, any person other than the parties hereto and the indemnified persons (it being agreed that (i) each Initial Lender reserves the right in its sole
discretion at any time to assign and delegate all or a portion of its commitments in respect of the Facilities hereunder, and to allocate all or a portion of its fees payable in connection therewith, to one or more of its affiliates, provided
that no such assignment or delegation shall relieve such Initial Lender of any of its obligations hereunder or under the Credit Documentation, including of any obligation in respect of its commitment in respect of the Facilities, in the event such
affiliate shall fail to perform such obligation in accordance with the terms hereof or of the Credit Documentation, as applicable and (ii) the Initial Lenders have the right to syndicate the Facilities and receive commitments with respect
thereto, provided that, except as contemplated under clause (b) of this paragraph, (x) no Initial Lender may assign all or any portion of its commitments hereunder prior to the Closing Date and (y) each Initial Lender shall
retain exclusive control over all rights and obligations with respect to the commitments hereunder until the Closing Date has occurred). This Commitment Letter may not be amended or waived except by an instrument in writing signed by you and each
Commitment Party; provided that (a) the Borrower shall have the right, upon prior written notice to the Arrangers, to 

 7 
  

 
terminate this Commitment Letter and the commitments hereunder, subject to the provisions of the second to last paragraph hereof and (b) any waiver or amendment by the Borrower prior to the
Misys Closing shall be approved by the Audit Committee of the Borrower’s Board of Directors. 
 This Commitment Letter may
be executed in any number of counterparts, each of which shall be an original, and all of which, when taken together, shall constitute one agreement. Delivery of an executed signature page of this Commitment Letter by email or facsimile transmission
shall be effective as delivery of a manually executed counterpart hereof. This Commitment Letter and the Fee Letter are the only agreements that have been entered into among us with respect to the Facilities and set forth the entire understanding of
the parties with respect thereto. Those matters that are not covered by the provisions hereof and of the Term Sheet are subject to the approval and agreement of the Commitment Parties and the Borrower. 

This Commitment Letter shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York;
provided, however, that the interpretation of the definition of “Borrower Material Adverse Effect” for purposes of this Commitment Letter shall be governed by, and construed and interpreted in accordance with, the laws of the
State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. Each party hereto consents to the exclusive jurisdiction and venue of the state or federal courts located in the City of New
York. Each party hereto irrevocably waives, to the fullest extent permitted by applicable law, (a) any objection that it may now or hereafter have to the laying of venue of any such legal proceeding in the state or federal courts located in the
City of New York and (b) any right it may have to a trial by jury in any suit, action, proceeding, claim or counterclaim brought by or on behalf of any party related to or arising out of this Commitment Letter, the Fee Letter, the Term Sheet,
the transactions contemplated hereby or the performance of services hereunder. 
 This Commitment Letter is delivered to you on
the understanding that neither this Commitment Letter, the Term Sheet or the Fee Letter nor any of their terms or substance shall be disclosed, directly or indirectly, to any other person (including, without limitation, other potential providers or
arrangers of financing) except (a) to your officers, directors, agents and advisors and, on a confidential basis, those of the Target and Misys who are directly involved in the consideration of this matter (except that the Fee Letter may only
be disclosed to the Target or Misys in a mutually agreed upon redacted form), (b) as may be compelled in a judicial or administrative proceeding or as otherwise required by law (in which case you agree to inform us promptly thereof to the
extent permitted by applicable law) or (c) with our prior written consent, provided, that the foregoing restrictions shall cease to apply (except in respect of the Fee Letter and its terms and substance) after this Commitment Letter has
been accepted by you. 
 Each Commitment Party and its affiliates will use all Confidential Information (as defined below)
solely for purposes that are subject to this Commitment Letter and the transactions contemplated thereby and shall treat confidentially all such Confidential Information, except that Confidential Information may be disclosed (a) to its and its
affiliates’ partners, directors, officers, employees and agents, including accountants, legal counsel and other advisors (it being understood that the persons to whom such disclosure is made will be informed of the confidential nature of such
Confidential Information), (b) to the extent requested or required by any state, Federal or foreign authority or examiner regulating such Commitment Party, (c) to the extent required by applicable law, rule or regulation or by any subpoena
or similar legal process, (d) in connection with any litigation or legal proceeding relating to this Commitment Letter or the Fee Letter or any other documentation in connection therewith or the enforcement of rights hereunder or thereunder or
to which such Commitment Party or any of its affiliates may be a party, (e) to any prospective Lender (it being understood that the persons to whom such disclosure is made will be informed of the confidential nature of such Confidential

 8 
  

 
Information and agree to keep such Confidential Information confidential to the same extent as required of each of the Commitment Parties hereinabove and below or as otherwise reasonably
acceptable to you and each Commitment Party, including as may be agreed in any confidential information memorandum or other marketing material), (f) with the consent of the Borrower, (g) on a confidential basis, to any rating agency when
required by such rating agency or (h) to the extent such Confidential Information (i) becomes publicly available other than as a result of a breach of this paragraph or (ii) becomes available to such Commitment Party on a
nonconfidential basis from a source other than the Borrower or any of its subsidiaries, officers, directors, employees or advisors. For the purposes of this paragraph, “Confidential Information” means all information received from
the Borrower or any of its subsidiaries, officers, directors, employees or advisors relating to the Borrower or its businesses, other than any such information that is available to the Commitment Parties on a nonconfidential basis prior to
disclosure by the Borrower. The obligations of the Commitment Parties under this paragraph shall remain in effect until the earlier of (i) one year from the date of termination of the commitments and agreements of the Commitment Parties
hereunder and (ii) the date the Credit Documentation becomes effective, at which time any confidentiality undertaking in the Credit Documentation shall supersede the provisions of this paragraph. 

Each of the Commitment Parties hereby notifies you that, pursuant to the requirements of the USA Patriot Act, Title III of Pub. L. 107-56
(signed into law on October 26, 2001) (the “Patriot Act”), it is required to obtain, verify and record information that identifies the Borrower and each Guarantor (as defined in the Term Sheet), which information includes names
and addresses and other information that will allow such Commitment Party to identify the Borrower and each Guarantor in accordance with the Patriot Act. 

The compensation, reimbursement, indemnification and confidentiality, governing law, consent to jurisdiction and waiver of jury trial
provisions contained herein and in the Fee Letter and any other provision herein or therein which by its terms expressly survives the termination of this Commitment Letter shall remain in full force and effect regardless of whether definitive
financing documentation shall be executed and delivered and notwithstanding the termination of this Commitment Letter or the commitments hereunder; provided that the reimbursement, confidentiality and indemnification provisions hereunder
(other than the confidentiality of the Fee Letter and the contents thereof) shall be superseded by the reimbursement, confidentiality and indemnification provisions of the Credit Documentation upon the effectiveness thereof. 

Notwithstanding any other provision of this Commitment Letter, the Term Sheet or the Fee Letter to the contrary, in the event that, prior
to the consummation of the Initial Share Repurchase and the Misys Offering (collectively, the “Misys Closing”) or, if the Misys Closing does not occur, at any time after the date hereof (i) there is any action or determination
to be made by us hereunder that would require approval of the Borrower’s Board of Directors or any committee thereof, (ii) there is any action, suit, proceeding, litigation or arbitration between the Borrower and Misys or (iii) there
is any disputed claim or demand (including any claim or demand relating to enforcing any remedy under this Commitment Letter, the Term Sheet or the Fee Letter) by the Borrower against Misys, or by Misys against the Borrower, all actions or
determinations of the Borrower prior to the Misys Closing or, if the Misys Closing does not occur, at any time after the date hereof or any determinations of the Borrower relating to any such action, suit, proceeding, litigation, arbitration, claim
or demand (including all determinations by the Borrower whether to institute, compromise or settle any such action, suit, proceeding, litigation, arbitration, claim or demand and all determinations by the Borrower relating to the prosecution or
defense thereof), shall be made and approved by the Audit Committee of the Borrower’s Board of Directors. 

 9 
  

 If the foregoing correctly sets forth our agreement, please indicate your acceptance of the
terms hereof and of the Term Sheet and the Fee Letter by returning to us executed counterparts hereof and of the Fee Letter not later than 5:00 p.m., New York City time, on June 9, 2010. This offer will automatically expire at such time if we
have not received such executed counterparts in accordance with the preceding sentence. 

 We are pleased to have been given the opportunity to assist you in connection with this
important financing. 
  

			
	Very truly yours,
	
	J.P. MORGAN SECURITIES INC.
		
	By:	 	 /s/ James McHugh

	Name:	 	James McHugh
	Title:	 	Executive Director
	
	JPMORGAN CHASE BANK, N.A.
		
	By:	 	 /s/ Krys Szremski

	Name:	 	Krys Szremski
	Title:	 	Vice President

 [Commitment Letter]

			
	BARCLAYS BANK PLC
		
	By:	 	 /s/ John Skorbe

	Name:	 	John Skorbe
	Title:	 	Managing Director

 [Commitment
Letter] 

			
	UBS SECURITIES LLC
		
	By:	 	 /s/ David W. Barth

	Name:	 	David W. Barth
	Title:	 	Managing Director
		 	High Yield Capital Markets
		
	By:	 	 /s/ Michael Lawton

	Name:	 	Michael Lawton
	Title:	 	Director
	
	UBS LOAN FINANCE LLC
		
	By:	 	 /s/ David W. Barth

	Name:	 	David W. Barth
	Title:	 	Managing Director
		 	High Yield Capital Markets
		
	By:	 	 /s/ Michael Lawton

	Name:	 	Michael Lawton
	Title:	 	Director

 [Commitment Letter]

 Accepted and agreed to as of 

the date first written above by: 
  

			
	ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.
		
	By:	 	 /s/ William J. Davis

	Name:	 	William J. Davis
	Title:	 	Chief Financial Officer

 [Commitment
Letter] 

 Schedule I 

SOURCES AND USES TABLE 
  

						
	 Sources:
	  		  		
		  	Term Loans	  	$	570,000,000
		  		  	 	 
		  	Revolving
Loans1	  	$	0
		  		  	 	 
		  	Cash on Hand	  	$	30,300,000
		  		  	 	 
		  	        Total Sources	  	$	600,300,000
		  		  	 	 
	 Uses:
	  		  		
		  	Initial Share Repurchase	  	$	577,400,000
		  		  	 	 
		  	Payment of Fees and
Expenses2	  	$	22,900,000
		  		  	 	 
		  	        Total Uses	  	$	600,300,000
		  		  	 	 

  

	1
	 $150,000,000 availability. 

	2
	 Includes estimated OID. 

[Commitment Letter] 

 EXHIBIT A 

 
  

ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC. 

CREDIT FACILITIES 

Summary of Terms and Conditions 
  

 

Allscripts-Misys Healthcare Solutions, Inc. (the “Borrower”) intends to (a) acquire all of the outstanding capital
stock of the company separately identified to the Lenders (as defined below) as “Electron” (the “Target”) solely in exchange for newly issued shares of common stock of the Borrower pursuant to a merger agreement (the
“Merger Agreement”) to be entered into with the Target (the “Electron Acquisition”) and (b) enter into an agreement (the “Misys Agreement”) with Misys plc (“Misys”) pursuant to
which (i) the Borrower will exchange newly issued shares of common stock of the Borrower for the capital stock of a US subsidiary of Misys (“Newco”) holding 61,308,295 of the outstanding shares of common stock of the Borrower
held by Misys; (ii) the Borrower will agree initially to repurchase outstanding shares of common stock of the Borrower (the “Misys Shares”) indirectly owned by Misys for an aggregate purchase price of approximately $577,400,000
(which Misys Shares will be immediately cancelled) (the “Initial Share Repurchase”), (iii) the Borrower will also agree to purchase additional Misys Shares at the direction of Misys for an aggregate purchase price of
approximately $101,600,000 upon consummation of the Electron Acquisition (which Misys Shares will also be immediately cancelled) (the “Second Share Repurchase” and, together with the Initial Share Repurchase, the “Share
Repurchases”)) and (iv) the Borrower will agree to assist with a secondary offering of Misys Shares in connection with the Transactions (as defined below) (the “Misys Offering”). In connection with the Transactions,
the Borrower wishes to establish $720,000,000 in senior secured credit facilities (the “Facilities”), the proceeds of which would be available to finance the Share Repurchases, the payment of fees and expenses in connection with the
Transactions and the ongoing working capital and general corporate needs of the Borrower and its subsidiaries. References herein to the “Transactions” shall include the Share Repurchases, the entering into of the Facilities and, if
consummated, the Electron Acquisition. The sources and uses of funding for the Transaction are described in the Sources and Uses Table (the “Table”) attached hereto as Schedule I. Set forth below is a statement of the terms and
conditions for the Facilities: 
  

			
	 I.       PARTIES

		
	Borrower:	  	The Borrower.
		
	Guarantors:	  	The Borrower’s direct and indirect, existing and future, material domestic subsidiaries other than Newco (collectively, the “Guarantors”; the Borrower and
the Guarantors, collectively, the “Loan Parties”).
		
	Lead Arrangers and Bookrunners:	  	J.P. Morgan Securities Inc., Barclays Capital, the investment banking division of Barclays Bank PLC (“Barclays Capital”) and UBS Securities LLC (in such
capacity, the “Arrangers”).
		
	Administrative Agent:	  	JPMorgan Chase Bank, N.A. (“JPMorgan Chase Bank” and, in such capacity, the “Administrative Agent”).

			
		
	Syndication Agent:	  	 Barclays Capital.

		
	Documentation Agent:	  	UBS Loan Finance LLC (“UBS”).
		
	Lenders:	  	A syndicate of banks, financial institutions and other entities, including JPMorgan Chase Bank, Barclays Bank PLC and UBS, arranged by the Arrangers in consultation with the
Borrower (collectively, the “Lenders”).
	
	 II.     TYPES AND AMOUNTS OF FACILITIES

		
	 A.     Term Facility
	  	
		
	Type and Amount:	  	A six-year term loan facility (the “Term Facility”) in the amount of $570,000,000 (the loans thereunder, the “Term Loans”). The Term Loans shall be
repayable in 24 quarterly installments, the first 23 of which shall equal 0.25% of the initial aggregate principal amount of the Term Loans with the remaining principal balance due and payable on the sixth anniversary of the Closing
Date.
		
	Availability:	  	The Term Loans shall be made in a single drawing on the Closing Date.
		
	Purpose:	  	The proceeds of the Term Loans shall be used to finance a portion of the Share Repurchases and to pay fees and expenses related to the Transactions.
		
	 B.     Revolving Facility
	  	
		
	Type and Amount:	  	A five-year revolving facility (the “Revolving Facility”; the commitments thereunder, the “Revolving Commitments”) in the amount of $150,000,000
(the loans thereunder, together with (unless the context otherwise requires) the Swingline Loans referred to below, the “Revolving Loans”; and together with the Term Loans, the “Loans”).
		
	Availability:	  	The Revolving Facility shall be available on a revolving basis during the period commencing on the Closing Date and ending on the date that is five years after the Closing Date (the
“Revolving Termination Date”).
		
	Maturity:	  	The Revolving Termination Date.
		
	Letters of Credit:	  	A portion of the Revolving Facility not in excess of $50,000,000 shall be available for the issuance of letters of credit (the “Letters of Credit”) by JPMorgan
Chase Bank (in such capacity, the “Issuing Lender”), including letters of credit in certain foreign currencies to be agreed. No Letter of Credit shall have an

 

 2 

			
		  	expiration date after the earlier of (a) one year after the date of issuance and (b) five business days prior to the Revolving Termination Date, provided that (i) any
Letter of Credit with a one-year tenor may provide for the renewal thereof for additional one-year periods (which shall in no event extend beyond the date referred to in clause (b) above) and (ii) any Letter of Credit may have an expiry date later
than the date referred to in clause (b) above if at the time of issuance the Borrower agrees to cash collateralize the obligations with respect to such Letter of Credit no later than 30 days prior to the Revolving Termination Date (or, if later, at
the time of issuance) by providing a deposit of cash in an amount equal to 105% of the face amount of such Letter of Credit on terms reasonably satisfactory to the Issuing Lender.
		
		  	Drawings under any Letter of Credit shall be reimbursed by the Borrower (whether with its own funds or with the proceeds of Revolving Loans) on the same business day (or on the
next business day if notice of such drawing is received after 10:00 a.m.). To the extent that the Borrower does not so reimburse the Issuing Lender, the Lenders under the Revolving Facility shall be irrevocably and unconditionally obligated to fund
participations in the reimbursement obligation on a pro rata basis.
		
	Swingline Loans:	  	A portion of the Revolving Facility not in excess of $10,000,000 shall be available for swingline loans (the “Swingline Loans”) from JPMorgan Chase Bank on
same-day notice. Any Swingline Loans will reduce availability under the Revolving Facility on a dollar-for-dollar basis. Each Lender under the Revolving Facility shall be unconditionally and irrevocably required to purchase, under certain
circumstances, a pro rata participation in each Swingline Loan.
		
	Purpose:	  	The proceeds of the Revolving Loans shall be used to finance (a) a portion of the Transactions and to pay related fees and expenses and (b) the working capital needs and general
corporate purposes of the Borrower and its subsidiaries, including financing of permitted acquisitions.
		
	 C.     Incremental Facility
	  	
		
		  	The Borrower shall be permitted, without the consent of any Lender other than the Lenders providing the Incremental Facility, to add one or more incremental term loan facilities
(each such term loan facility, an “Incremental Term Facility”) to the Facilities and/or increase commitments under the Revolving Facility (each such increase, an “Incremental Revolving Facility”; the Incremental
Term Facilities and the Incremental Revolving Facilities are collectively referred to as “Incremental Facilities”) in an aggregate amount of up to $250,000,000; provided that (i) no existing Lender will be required
to

  

 3 

			
		 	participate in any such Incremental Facility without its consent, (ii) no event of default or default under the Credit Documentation (as defined below) exists or would exist after
giving effect thereto, (iii) the Borrower is in compliance, on a pro forma basis after giving effect to any borrowing under such Incremental Facility with the financial covenants in the Credit Documentation recomputed as of the last
day of the most recently ended fiscal quarter of the Borrower for which financial statements are available, (iv) the maturity date of any such Incremental Term Facility shall be no earlier than the maturity date of the Term Facility, and the
weighted average life of such Incremental Term Facility shall be not shorter than the then remaining weighted average life of the Term Facility, (v) the interest rate margins and (subject to clause (iv)) amortization schedule applicable to any
Incremental Term Facility shall be determined by the Borrower and the lenders thereunder; provided that in the event that the applicable interest rate margins for the Incremental Term Facility are more than 0.50% per annum higher than the
interest rate margins for the Term Facility, then the interest rate margins for the Term Facility shall be increased so that such interest rate margins are equal to the interest rate margins for such Incremental Term Facility minus 0.50% per annum,
(vi) if the Revolving Facility is still in effect, any Incremental Revolving Facility shall be on terms and pursuant to documentation applicable to the Revolving Facility, and (vii) any Incremental Term Facility shall be on terms and pursuant to
documentation to be determined by the Borrower and the lenders thereunder; provided that, to the extent such terms and documentation are not consistent with the Term Facility (except to the extent permitted by clause (iv) or (v) above), they
shall be reasonably satisfactory to the Administrative Agent; provided, further, that in determining the interest rate margins applicable to any Incremental Term Facility and the Term Facility, (x) original issue discount
(“OID”) or upfront fees (which shall be deemed to constitute like amounts of OID) paid by the Borrower to the Lenders under the Term Facility or such Incremental Term Facility in the initial primary syndication thereof shall be
included and equated to interest rate (with OID being equated to interest based on an assumed four-year life to maturity), (y) the excess of the Closing Date LIBOR Floor (as defined below) over three-month LIBOR and the excess of the Closing Date
ABR Floor (as defined below) over the Base Rate, in each case without duplication as of the Closing Date, shall be equated to interest margin on the Term Facility for purposes of the foregoing and (z) the excess of any LIBOR “floor” over
three-month LIBOR and the excess of any ABR “floor” over the ABR, in each case without duplication as of the date of drawing of such Incremental Term Facility, shall be equated to interest margin on such Incremental Term Facility for
purposes of the foregoing.

  

 4 

			
	 III.    CERTAIN PAYMENT PROVISIONS

		
	Fees and Interest Rates:	  	As set forth on Annex I.
		
	Optional Prepayments and Commitment Reductions:	  	Loans may be prepaid and commitments may be reduced by the Borrower in minimum amounts to be agreed upon. Optional prepayments of the Term Loans shall be applied to the
respective installments thereof as determined by the Borrower. Optional prepayments of the Term Loans may not be reborrowed.
		
	Mandatory Prepayments:	  	The following amounts shall be applied to prepay the Term Loans, provided that no such prepayment under clauses (b) or (c) below shall be required to the extent that,
prior to or after giving effect thereto, the total leverage ratio is less than 2.5 to 1.0:
		
		  	(a) 100% of the net proceeds of any incurrence of indebtedness (other than indebtedness permitted under the Credit Documentation (subject to certain exceptions as may be
agreed)) after the Closing Date by the Borrower or any of its subsidiaries.
		
		  	(b) 100% of the net cash proceeds of any sale, or other disposition (including as a result of casualty or condemnation) by the Borrower or any of its subsidiaries of any
assets in excess of $5,000,000 in any fiscal year, except for the sale of inventory or obsolete or worn-out property in the ordinary course of business and subject to certain other customary exceptions to be agreed upon (including capacity for
reinvestment in productive assets of the kind then used or usable by the Borrower or any of its subsidiaries within one year (or eighteen months if a binding contract to use such proceeds shall have been entered into within such one-year period)).

		
		  	(c) the sum of (i) 50% of excess cash flow (to be defined) for each fiscal year of the Borrower (commencing with the 2012 fiscal year) minus (ii) any voluntary
prepayments of the Term Loans during such fiscal year.
		
		  	All such amounts shall be to the respective installments thereof ratably in accordance with the then outstanding amounts thereof. Mandatory prepayments of the Term Loans may not
be reborrowed.
		
	 IV.   COLLATERAL
	  	The obligations of each Loan Party in respect of the Facilities, and any swap agreements and, at the Borrower’s election, cash management arrangements provided by any Lender
(or any affiliate of a Lender), shall be secured by a perfected first priority security interest in all of its tangible and intangible assets (including, without limitation, intellectual property, material owned real property and all of the capital
stock of each

  

 5 

			
		  	Guarantor and, in the case of foreign subsidiaries, up to 65% of the capital stock of first tier material foreign subsidiaries) (collectively, the “Collateral”).
The Collateral shall exclude (i) assets (including vehicles) that are subject to certificated title statues, (ii) leasehold interests in real property, (iii) assets as to which the Administrative Agent shall determine in its sole reasonable
discretion that the cost of obtaining a security interest therein or perfection thereof are excessive in relation to the value of the security to be afforded thereby, (iv) assets as to which granting or perfecting such security interests would
violate (a) applicable law or (b) contracts evidencing or giving rise to such assets (but only to the extent such contractual provisions are not rendered ineffective by applicable law or otherwise unenforceable), (v) any contract in which the grant
of a security interest therein is prohibited thereby (but only to the extent such contractual provisions are not rendered ineffective by applicable law or otherwise unenforceable) and (vi) the capital stock of Newco and all shares of capital stock
of the Borrower owned by Newco. On the Closing Date, there shall be no requirement to provide (i) lockbox arrangements or control agreements relating to the Borrower’s or its subsidiaries’ bank or security accounts or (ii) mortgages or
other means of perfection or control other than through means of the filing of an initial financing statement under the Uniform Commercial Code or the delivery of stock certificates (endorsed in blank or with accompanying stock powers) or
instruments; control agreements relating to material bank and security accounts, mortgages and such other means of perfection or control may be required at a later date in the Administrative Agent’s reasonable discretion.
	
	V. CERTAIN CONDITIONS
		
	Initial Conditions:	  	The availability of the Facilities shall be conditioned upon the satisfaction of the following conditions precedent (the date upon which all such conditions precedent shall be
satisfied (which date shall not be later than December 9, 2010), the “Closing Date”):
		
		  	 (a) Each Loan Party shall have executed and delivered definitive financing documentation with respect to the Facilities setting
forth the terms set forth herein and as otherwise mutually agreed (the “Credit Documentation”).
  

(b) The Misys Agreement and related documentation required pursuant to the Misys Agreement to be executed on or prior to the date of the Initial
Share Repurchase (the “Misys Separation Documentation”) shall have been executed on terms reasonably satisfactory to the Arrangers (the review of which shall be conducted and concluded promptly and without the intent to hinder or
delay), and no provision thereof shall have been waived, amended, supplemented or otherwise modified in any respect that is material and adverse to the Lenders without

 

 6 

			
		 	approval of the Arrangers, it being agreed that the draft Misys Agreement and each of the Exhibits thereto provided to the Arrangers on June 9, 2010 shall be reasonably
satisfactory. The Initial Share Repurchase shall have been consummated, or substantially simultaneously with the initial borrowing under the Facilities shall be consummated, in accordance with the terms of the Misys Separation Documentation without
material waiver, amendment, supplement or modification thereof, except as approved by the Arrangers (the review of which shall be conducted and concluded promptly and without the intent to hinder or delay).
		
		 	(c) All of the existing indebtedness of the Borrower and its subsidiaries under the Borrower’s existing credit facility with the Administrative Agent shall have been
repaid in full (or, in the case of letters of credit issued thereunder, deemed to be issued pursuant to the Credit Documentation, terminated, cash collateralized or otherwise supported with Letters of Credit issued pursuant to the Credit
Documentation).
		
		 	(d) The Lenders, the Administrative Agent and the Arrangers shall have received all fees required to be paid, and all expenses required to be paid for which invoices have been
presented not less than one business day prior to the Closing Date.
		
		 	(e) All governmental and third party approvals necessary to consummate the Transactions (other than the Electron Acquisition and the Second Share Repurchase) and the financing
contemplated hereby (including shareholder approvals) shall have been obtained and shall be in full force and effect, and all applicable waiting periods shall have expired without any action being taken or threatened by any competent authority that
would restrain, prevent or otherwise impose materially adverse conditions on the Transactions (other than the Electron Acquisition and the Second Share Repurchase) or the financing thereof.
		
		 	(f) The Borrower shall have delivered (i) audited consolidated financial statements of the Borrower for the two most recent fiscal years as to which such financial
statements are available and (ii) unaudited interim consolidated financial statements of the Borrower for each quarterly period ended subsequent to the date of the latest financial statements delivered pursuant to clause (i) of this
paragraph as to which such financial statements are available.
		
		 	(g) The Borrower shall have delivered a pro forma consolidated balance sheet of the Borrower and its subsidiaries as at the date of the most recent
consolidated balance sheet delivered pursuant to the preceding paragraph, and a pro forma statement of operations for the twelve-month period ending on such balance

 

 7 

			
		 	sheet date, in each case prepared after giving effect to the consummation of the Transactions (other than the Electron Acquisition and the Second Share Repurchase) and the
financings contemplated hereby as if such transactions had occurred on such date or on the last day of such period, as the case may be.
		
		 	(h) The Borrower shall have used commercially reasonable efforts to receive a corporate credit rating of the Borrower from each of Standard & Poor’s Ratings Group
(“S&P”) and Moody’s Investors Service, Inc. (“Moody’s”).
		
		 	(i) The Administrative Agent shall have received the results of a recent bring down lien search in each relevant jurisdiction with respect to the Borrower and the Guarantors,
and such search shall reveal no liens on any of the Collateral except for liens permitted by the Credit Documentation, liens to be discharged on or prior to the Closing Date and liens disclosed in the lien search results delivered to the
Administrative Agent prior to the date of execution of this Commitment Letter.
		
		 	(j) Except as otherwise provided in “Collateral” above, all documents and instruments required to perfect the Administrative Agent’s security interest in the
Collateral (including UCC-1 financing statements, delivery of stock certificates and undated stock powers executed in blank) shall have been executed and be in proper form for filing.
		
		 	(k) The Administrative Agent shall have received a solvency certificate from the chief financial officer of the Borrower (or, at the Borrower’s option, a solvency opinion
from an independent investment bank or valuation firm of nationally recognized standing) that shall document the solvency of the Borrower and its subsidiaries (on a going concern and consolidated basis) after giving effect to the Transactions (other
than the Electron Acquisition).
		
		 	 (l) The Administrative Agent shall have received such legal opinions (including from special and local counsel), closing
certificates, and similar closing documents as are customary for financings of this type, in each case, as may be reasonably requested by the Administrative Agent.
  

(m) The Administrative Agent shall have received all documentation and other information required by regulatory authorities under applicable
“know your customer” and anti-money laundering rules and regulations, including the PATRIOT Act.
  

(n) The pro forma ratio of total indebtedness of the Borrower and its subsidiaries to EBITDA (calculated consistent (except
to

  

 8 

			
		  	the extent mutually agreed) with the Borrower’s existing credit agreement and, if the Electron Acquisition closes substantially simultaneous with or before the Closing Date,
giving pro forma effect to the Electron Acquisition) shall not exceed 4.0 to 1.0, and the Borrower shall have provided reasonably satisfactory support for such calculation.
		
	On-Going Conditions:	  	The making of each extension of credit shall be conditioned upon (a) the accuracy in all material respects of all representations and warranties in the Credit Documentation
(including, without limitation, the material adverse change and litigation representations) and (b) there being no default or event of default in existence at the time of, or after giving effect to the making of, such extension of credit. As used
herein and in the Credit Documentation, a “material adverse change” shall mean any event, development or circumstance that has resulted or could reasonably be expected to result in (a) a material adverse effect on the business, financial
condition or results of operations of the Borrower and its subsidiaries taken as a whole or (b) a material impairment in the ability of the Loan Parties, taken as a whole, to perform their obligations under the Credit Documentation or the rights and
remedies of the Administrative Agent and the Lenders thereunder; provided that for purposes of the initial funding of the Facilities on the Closing Date and the funding of the Second Share Repurchase “material adverse change” shall
be defined as “Borrower Material Adverse Effect” (as defined in the Commitment Letter).
	
	 VI.   CERTAIN DOCUMENTATION MATTERS

		
		  	The Credit Documentation shall contain the following representations, warranties, covenants and events of default (in each case, applicable to the Borrower and its subsidiaries),
subject to customary exceptions, materiality qualifications and grace periods and such other exceptions as are mutually agreed:
		
	Representations and Warranties:	  	Financial statements (including pro forma financial statements); absence of undisclosed liabilities as of the Closing Date; no material adverse change; corporate existence;
compliance with law; corporate power and authority; enforceability of Credit Documentation; no conflict with law, charter documents or contractual obligations; no material litigation; governmental consents; ownership of property; liens; intellectual
property; taxes; Federal Reserve regulations; labor matters, ERISA; Investment Company Act and other regulations; subsidiaries; use of proceeds; environmental matters; accuracy of disclosure; creation and perfection of security interests; solvency;
Regulation H; and delivery of the Misys Agreement and certain other material documents delivered in connection therewith.

  

 9 

			
	Affirmative Covenants:	  	Delivery of quarterly and annual financial statements, reports, accountants’ letters, projections, officers’ certificates and other information reasonably requested by
the Lenders (through the Administrative Agent); retirement of any stock repurchased in Share Repurchases to the extent the Share Repurchases are financed with proceeds of the Facilities; payment of taxes; continuation of business and maintenance of
existence and material rights and privileges; compliance with laws; maintenance of property and insurance; maintenance of books and records; right of the Administrative Agent and the Lenders to inspect property and books and records (unless a
default shall be continuing or the Administrative Agent reasonably believes an event has occurred that has a material adverse effect, (i) to be limited to once annually, and (ii) neither the Borrower nor any of its subsidiaries shall be required to
pay or reimburse any costs or expenses incurred by any Lender (other than the Administrative Agent) in connection therewith); notices of defaults, litigation and other events having a material adverse effect; compliance with environmental laws; and
further assurances (including, without limitation, with respect to security interests in after-acquired property).
		
	Financial Covenants:	  	 Commencing with the first fiscal quarter ending after the Closing Date, minimum interest coverage ratio, tested quarterly on a
trailing twelve-month basis for the Borrower and its consolidated subsidiaries, of not less than 3.5 to 1.0, with step-ups to be agreed between the Borrower and the Administrative Agent (interest coverage ratio to be defined as the ratio of EBIT to
cash interest expense, calculated consistent (except to the extent mutually agreed) with the Borrower’s existing credit
agreement).1 The Borrower shall be entitled to add back to
EBIT transaction and integration costs and expenses relating to the Electron Acquisition, subject to a cap to be agreed.
  

Maximum leverage ratio, tested quarterly on a trailing twelve-month basis for the Borrower and its consolidated subsidiaries, not greater than 4.0 to 1.0,
with step-downs to be agreed between the Borrower and the Administrative Agent (leverage ratio to be defined as the ratio of indebtedness to EBITDA, calculated consistent (except to the extent mutually agreed) with the Borrower’s existing
credit agreement).2 The Borrower shall be entitled to add
back to EBITDA transaction and integration costs and expenses relating to the Electron Acquisition, subject to a cap to be agreed.

 

	1
	 Upon consummation of the Electron Acquisition, the minimum interest coverage ratio will increase to 4.5 to 1.0 and remain at such level for the term of
the Facilities. 

	2
	 Upon consummation of the Electron Acquisition, the maximum leverage ratio will decrease to 3.0 to 1.0 and remain at such level for the term of the
Facilities. 

  

 10 

			
	Negative Covenants:	  	 Limitations on: indebtedness (including guarantee obligations); liens; mergers (permitting the Permitted Electron Acquisition (as
defined below)), consolidations, liquidations and dissolutions; sales of assets; dividends and other payments in respect of capital stock provided that (i) dividends and such other payments shall be permitted so long as the Borrower’s leverage
ratio is less than 1.75 to 1.0 and (ii) if the Borrower’s leverage ratio is greater than or equal to 1.75 to 1.0, dividends and such other payments shall be subject to baskets to be
agreed3; acquisitions (other than (i) the Electron
Acquisition as long as (x) consummated in accordance with the description in the first paragraph of this Term Sheet and (y) since December 31, 2009, no Target Material Adverse Effect (as defined below) has occurred (the “Permitted
Electron Acquisition”) and (ii) provided that other non-hostile acquisitions shall be permitted so long as (in the case of this clause (ii)) the Borrower is in pro forma compliance with financial covenants, no default has occurred and is
continuing, and the Borrower’s leverage ratio is less than 2.0 to 1.0); investments (permitting the Permitted Electron Acquisition) , loans and advances; prepayments and modifications of subordinated debt instruments; transactions with
affiliates; sale-leasebacks; hedging arrangements; negative pledge clauses adversely affecting the Administrative Agent’s liens on the Collateral and clauses restricting subsidiary distributions; changes in lines of business; business and
assets of Newco (to be limited to holding of common stock of the Borrower and any transactions expressly contemplated in the Misys Agreement); and amendments to the Misys Agreement and other material transaction documents.

 
 “Target Material Adverse Effect” shall mean, except as set forth in
Section 6.3(c) of the Company Disclosure Letter or in the Company SEC Disclosure (as such terms are defined in the Merger Agreement), any event, occurrence, fact, condition, effect, change or development that, individually or when taken together
with all other events, occurrences, facts, conditions, effects, changes or developments, is, or is reasonably expected to be, materially adverse to the business, assets, liabilities (contingent or otherwise), financial condition or results of
operations of the Target and its subsidiaries, taken as a whole; provided, however, that none of the following shall constitute, and no event, effect, change or development to the extent resulting from any of the following, shall
constitute or be taken into account in determining whether there has been a “Target Material Adverse Effect”: (i) factors affecting the national or world economy or financial, banking, credit, securities or commodities markets, taken as a
whole, except to the extent the Target is adversely affected in a disproportionate manner as compared to other comparable companies in the industry in which the Target operates; (ii) conditions generally affecting the industries in which the Target
or its subsidiaries operate, except to the extent the Target is adversely affected in a disproportionate manner as compared to other comparable companies in the industry in

 

	3
	 Note: Inclusion of the Restricted Payment baskets set forth above requires corporate ratings of the Borrower of BB/Ba2 or higher.

 

  

 11 

			
		  	which the Target operates; (ii) conditions generally affecting the industries in which the Target or its subsidiaries operate, except to the extent the Target is adversely
affected in a disproportionate manner as compared to other comparable companies in the industry in which the Target operates; (iii) factors resulting from or arising out of the announcement of the Merger Agreement, the Misys Agreement or the
transactions contemplated thereby (including any shareholder or derivative litigation arising from or relating to the Merger Agreement, the Misys Agreement or the transactions contemplated thereby) or the performance of the Merger Agreement or the
Misys Agreement; (iv) any circumstances relating to the loss in whole or in part of any business relationship with any customer or client of the Target or any of its subsidiaries set forth in Section 9.1 of the Company Disclosure Letter, other than
as a result of the valid termination by a customer or client of any written contract due to the breach by the Target or any of its subsidiaries of its obligations under any such written contract to license material intellectual property rights owned
by the Target or any of its subsidiaries or perform material services related to such licenses required to be licensed or performed, respectively, under such written contract; (v) any failure by the Target to meet any analysts’ revenue or
earnings projections or Target guidance, in and of themselves, or any failure of the Target to meet any of the Target’s internal or published revenue or earnings projections or forecasts, in and of themselves (it being understood that any
event, occurrence, fact, condition, effect, change or development giving rise to any such failure or decline, other than an event, occurrence, fact, condition, effect, change or development set forth in clauses (i) through (iv) above or clauses (vi)
through (ix) below, may be deemed to constitute, and may be taken into account in determining whether there has been, or is reasonably expected to be, a Target Material Adverse Effect); (vi) any effect resulting from changes in Laws or accounting
principles, in each case, after the date of the Merger Agreement; (vii) any effect resulting from any outbreak or escalation of hostilities, the declaration of a national emergency or war, or the occurrence of any act of terrorism; (viii) any event,
effect, change or development arising or resulting from any material breach of the Merger Agreement by the Borrower or its affiliates; or (ix) any increase in the cost of or decrease in the availability of financing to the Borrower or its
subsidiaries with respect to the Share Repurchases.
		
	Events of Default:	  	Nonpayment of principal when due; nonpayment of interest, fees or other amounts after a grace period of five business days; material inaccuracy of a representation or warranty
when made; violation of a covenant (subject, in the case of certain affirmative covenants, to customary grace periods); cross-default to indebtedness in excess of $20,000,000; bankruptcy events; certain ERISA events; judgments in excess of
$20,000,000 (after deduction of any amount that is covered by a valid and binding

  

 12 

			
		  	insurance policy in favor of the relevant Loan Party); actual (or any Loan Party or affiliate of a Loan Party shall assert) invalidity of any guarantee or security document; and
a change of control (the definition of which is to be agreed upon).
		
	Voting:	  	Amendments and waivers with respect to the Credit Documentation shall require the approval of Lenders holding more than 50% of the aggregate amount of the Term Loans and Revolving
Commitments, except that, subject to the defaulting lender provisions as provided below, (a) the consent of each Lender directly affected thereby shall be required with respect to (i) reductions in the amount or extensions of the scheduled date of
any amortization or final maturity of any Loan, (ii) reductions in the rate of interest or any fee or extensions of any due date thereof and (iii) increases in the amount or extensions of the expiry date of any Lender’s commitment and (b) the
consent of 100% of the Lenders shall be required with respect to (i) reductions of any of the voting percentages, (ii) releases of all or substantially all the collateral and (iii) releases of all or substantially all the Guarantors. In addition,
“class” voting requirements with respect to each Facility adversely affected thereby will apply to modifications affecting waiver of post-default increase in interest rate, reduction or elimination of mandatory prepayment requirements and
changes in the pro rata treatment provisions.
		
	Assignments and Participations:	  	The Lenders shall be permitted to assign all or a portion of their Loans and commitments with the consent, not to be unreasonably withheld, of (a) the Borrower (such consent not to
be unreasonably withheld or delayed) unless (i) the assignee is a Lender, an affiliate of a Lender or an approved fund or (ii) an event of default has occurred and is continuing, (b) the Administrative Agent, unless a Term Loan is being assigned to
a Lender, an affiliate of a Lender or an approved fund, and (c) the Issuing Lender, unless a Term Loan is being assigned. Non-pro rata assignments shall be permitted. In the case of partial assignments (other than to another Lender, an affiliate of
a Lender or an approved fund), the minimum assignment amount shall be $1,000,000 (in the case of the Term Facility) and $5,000,000 (in the case of the Revolving Facility), in each case unless otherwise agreed by the Borrower and the Administrative
Agent. The Administrative Agent shall receive a processing and recordation fee of $3,500 in connection with all assignments payable by the assignor or assignee. The Lenders shall also be permitted to sell participations in their Loans. Participants
shall have the same benefits as the Lenders with respect to yield protection and increased cost provisions subject to customary limitations. Voting rights of participants shall be limited to those matters set forth in clause (a) under
“Voting” with respect to which the affirmative vote of the Lender from which it purchased its participation would be required. Pledges of Loans in accordance with applicable law shall be permitted without
restriction.

  

 13 

			
	Defaulting Lenders:	  	The Credit Documentation will contain provisions regarding Defaulting Lenders reasonably acceptable to the Administrative Agent and the Borrower.
		
	Yield Protection:	  	The Credit Documentation shall contain customary provisions (a) protecting the Lenders against increased costs or loss of yield resulting from changes in reserve, tax, capital
adequacy and other requirements of law and from the imposition of or changes in withholding or other taxes and (b) indemnifying the Lenders for “breakage costs” incurred in connection with, among other things, any prepayment of a
Eurodollar Loan (as defined in Annex I) on a day other than the last day of an interest period with respect thereto; provided that any request for any amount under clause (a) or (b) shall include reasonable details of the calculation thereof
and the Borrower’s liability shall not be retroactive for more than 180 days.
		
	Expenses and Indemnification:	  	The Borrower shall pay (a) all reasonable out-of-pocket expenses of the Administrative Agent and the Arrangers associated with the syndication of the Facilities and the
preparation, execution, delivery and administration of the Credit Documentation and any amendment or waiver with respect thereto (including the reasonable and documented fees, disbursements and other charges of one counsel to the Administrative
Agent and the Arrangers and, if necessary, one local counsel in any applicable jurisdiction and, in the case of a conflict of interest, one additional counsel per affected party and any specialist counsel, if reasonably necessary) and (b) all
out-of-pocket expenses of the Administrative Agent and the Lenders (including the fees, disbursements and other charges of counsel) in connection with the enforcement of the Credit Documentation.
		
		  	The Administrative Agent, the Arrangers and the Lenders (and their affiliates and their respective officers, directors, employees, advisors and agents) will have no liability
for, and will be indemnified and held harmless against, any losses, claims, damages, liabilities or expenses incurred in respect of the financing contemplated hereby or the use or the proposed use of proceeds thereof, except to the extent they
resulted from the gross negligence or willful misconduct of the relevant indemnified person or a material breach by the relevant indemnified person of the express contractual obligations under the Credit Documentation pursuant to a claim made by the
Borrower, in each case as determined by a final, nonappealable judgment of a court of competent jurisdiction.
		
	Governing Law and Forum:	  	State of New York; provided, however, that the interpretation of the definitions of “Borrower Material Adverse Effect” and

 

 14 

			
		  	“Target Material Adverse Effect” shall be governed by, and construed and interpreted in accordance with, the laws of the State of Delaware, regardless of the laws that
might otherwise govern under applicable principles of conflicts of laws.
		
	 Counsel to the Administrative

Agent and the Arrangers:
	  	Simpson Thacher & Bartlett LLP.

  

 15 

 Annex I 

 

			
		  	    INTEREST AND CERTAIN FEES
		
	Interest Rate Options:	  	The Borrower may elect that the Loans comprising each borrowing bear interest at a rate per annum equal to (a) the ABR plus the Applicable Margin or (b) the Eurodollar Rate plus
the Applicable Margin; provided, that all Swingline Loans shall bear interest at a rate per annum equal to the ABR plus the Applicable Margin.
		
		  	As used herein:
		
		  	“ABR” means the highest of (i) the rate of interest publicly announced by JPMorgan Chase Bank as its prime rate in effect at its principal office in New York
City (the “Prime Rate”), (ii) the federal funds effective rate from time to time plus 0.5% and (iii) the Eurodollar Rate for a one month interest period plus 1.0%; provided, however, that notwithstanding the rate
calculated in accordance with the foregoing, at no time shall ABR be deemed to be less than 2.50% per annum for the Term Facility (the “Closing Date ABR Floor”).
		
		  	“Applicable Margin” means with regard to Term Loans and Revolving Loans a percentage determined in accordance with the pricing grid attached hereto as Annex I-A.

		
		  	“Eurodollar Rate” means the rate (adjusted for statutory reserve requirements for eurocurrency liabilities) for eurodollar deposits for a period equal to one,
two, three or six months or, with respect to Revolving Loans, subject to availability to all affected Lenders, 7 or 14 days, (as selected by the Borrower) appearing on Reuters Screen LIBOR 01; provided, however, that notwithstanding
the rate calculated in accordance with the foregoing, at no time shall the Eurodollar Rate be deemed to be less than 1.50% per annum for the Term Facility (the “Closing Date LIBOR Floor”).
		
	Interest Payment Dates:	  	In the case of Loans bearing interest based upon the ABR (“ABR Loans”), quarterly in arrears.
		
		  	In the case of Loans bearing interest based upon the Eurodollar Rate (“Eurodollar Loans”), on the last day of each relevant interest period and, in the case of
any interest period longer than three months, on each successive date three months after the first day of such interest period.
		
	Commitment Fees:	  	The Borrower shall pay a commitment fee calculated at a rate per annum equal to 0.50% on the average daily unused portion of the Revolving Facility, payable quarterly in arrears.
Swingline Loans shall, for purposes of the commitment fee calculations only, not be deemed to be a utilization of the Revolving Facility. The Borrower shall not be required to pay a commitment fee in

			
		  	respect of the commitment for the Revolving Facility of any Lender for any period during which such Lender is a defaulting lender.
		
	Letter of Credit Fees:	  	The Borrower shall pay a fee on all outstanding Letters of Credit at a per annum rate equal to the Applicable Margin then in effect with respect to Eurodollar Loans under the
Revolving Facility on the face amount of each such Letter of Credit. Such fee shall be shared ratably among the Lenders participating in the Revolving Facility and shall be payable quarterly in arrears. The Borrower shall not be required to pay such
fee in respect of the commitment for the Revolving Facility of any Lender for any period during which such Lender is a defaulting lender.
		
		  	A fronting fee at a rate per annum equal to 0.125% on the face amount of each Letter of Credit shall be payable quarterly in arrears to the Issuing Lender for its own account. In
addition, customary administrative, issuance, amendment, payment and negotiation charges shall be payable to the Issuing Lender for its own account.
		
	Default Rate:	  	At any time when the Borrower is in default in the payment of any amount of principal due under the Facilities, all overdue amounts shall bear interest at 2% above the rate
otherwise applicable thereto. Overdue interest, fees and other amounts shall bear interest at 2% above the rate applicable to the relevant ABR Loans.
		
	Rate and Fee Basis:	  	All per annum rates shall be calculated on the basis of a year of 360 days (or 365/366 days, in the case of ABR Loans the interest rate payable on which is then based on the
Prime Rate) for actual days elapsed.

  

 2 

 Annex I-A 

The Applicable Margin for Revolving Loans and Term Loans shall be determined on the Closing Date based upon the rate per annum set
forth below opposite the applicable corporate ratings of the
Borrower:4 

 

											
	 	  	 Corporate Rating
	  	Applicable
Margin

Eurodollar Loans
(Term Loans)	  	Applicable Margin
Eurodollar Loans

(Revolving Loans)	  	Applicable
    Margin 
ABR    
Loans (Term
Loans)	  	Applicable
Margin 
ABR
Loans (Revolving
Loans
	Level I	  	 BB+ and Ba1 or
 any more
favorable
 rating, in each case
 with
stable outlook
 or better
	  	3.00-3.25%	  	2.50-2.75%	  	2.00-2.25%	  	1.50-1.75%
						
	Level II	  	 BB and Ba2, in
 each case
with
 stable outlook or
 better (but
not
 Level I)
	  	3.25-3.50%	  	2.75-3.00%	  	2.25-2.50%	  	1.75-2.00%
						
	Level III	  	 At neither Level I
 nor
Level II
	  	3.50-3.75%	  	3.00-3.25%	  	2.50-2.75%	  	2.00-2.25%

 For purposes of determining the
Applicable Margin, the applicable corporate ratings from both S&P and Moody’s will be required to qualify for the applicable level set forth above; provided that if the corporate ratings from S&P and Moody’s fall within
different levels, (i) the Applicable Margin will be based on the lower ratings level unless the higher applicable corporate rating is more than one level higher than the other corporate rating, in which case the Applicable Margin shall be the
level immediately above the level corresponding to such lower corporate rating. 
  

 

	4
	 Note: Applicable Margin for Term Loans will be fixed at closing based on the grid. Applicable Margin for Revolving Loans will initially be fixed at
closing based on the grid but will be subject to adjustment based on a leverage based grid to be agreed, commencing with the first fiscal quarter after the Closing Date.Purchase Agreement dated June 9, 2010

 Exhibit 10.1 

National Financial Partners Corp. 

$125,000,000 4.0% Convertible Senior Notes due 2017 

 
  

Purchase Agreement 

June 9, 2010 
 Goldman,
Sachs & Co. 
 200 West Street 

New York, NY 10282 
 Merrill Lynch, Pierce,
Fenner & Smith Incorporated 
 One Bryant Park 

New York, NY 10036 
 As representatives of the
several Purchasers named in Schedule I hereto (the “Purchasers”) 
 Ladies and Gentlemen: 

National Financial Partners Corp., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated
herein, to sell to the Purchasers, $125,000,000 aggregate principal amount of its 4.0% Convertible Senior Notes due 2017 (the “Notes”), and with respect to the grant by the Company to the Purchasers of the option described in
Section 2 hereof to purchase all or any part of an additional $15,000,000 aggregate principal amount of Notes to cover over-allotments, if any. The aforesaid $125,000,000 principal amount of the Notes to be purchased by the Purchasers (the
“Initial Securities”) and all or any part of the $15,000,000 aggregate principal amount of Notes subject to the option described in Section 2 hereof (the “Optional Securities,”) together with the Initial Securities are
herein referred to as the “Securities”. The Securities will be issued pursuant to an Indenture, to be dated on or around June 15, 2010 (the “Indenture”), between the Company and Wells Fargo Bank, National Association, as
trustee (the “Trustee”). The Securities are convertible into shares (the “Underlying Common Stock”) of the Company’s common stock, par value $0.10 per share (the “Stock”), in accordance with the terms of the
Securities and the Indenture. 
 It is understood and agreed that Goldman, Sachs & Co. and Merrill Lynch, Pierce,
Fenner & Smith Incorporated (the “Representatives”) are joint book-running managers for the offering of the Securities contemplated hereby and any determinations or other actions to be made under this Agreement by the
Representatives shall require the concurrence of each of the Representatives, unless as otherwise specified herein. 
 1. The
Company represents and warrants to, and agrees with, the Purchasers that: 
 (a) A preliminary offering circular,
dated June 9, 2010 (the “Preliminary Offering Circular”) and an offering circular, dated June 9, 2010 (the “Offering Circular”, have been prepared in connection with the offering of the Securities and shares of the
Stock issuable upon conversion thereof. The Preliminary Offering Circular, as amended and supplemented immediately prior to the Applicable Time (as defined in Section 1(b)), 

 
is hereinafter referred to the “Pricing Circular”. Any reference to the Preliminary Offering Circular, the Pricing Circular or the Offering Circular shall be deemed to refer to and
include the Company’s most recent Annual Report on Form 10-K and all subsequent documents filed with the United States Securities and Exchange Commission (the “Commission”) pursuant to Section 13(a), 13(c) or 15(d) of the United
States Securities Exchange Act of 1934, as amended (the “Exchange Act”) on or prior to the date of such circular and any reference to the Preliminary Offering Circular or the Offering Circular, as the case may be, as amended or
supplemented, as of any specified date, shall be deemed to include (i) any documents filed with the Commission pursuant to Section 13(a), 13(c) or 15(d) of the Exchange Act after the date of the Preliminary Offering Circular or the
Offering Circular, as the case may be, and prior to such specified date and (ii) any Additional Issuer Information (as defined in Section 5(f)) furnished by the Company prior to the completion of the distribution of the Securities; and all
documents filed under the Exchange Act and so deemed to be included in the Preliminary Offering Circular, the Pricing Circular or the Offering Circular, as the case may be, or any amendment or supplement thereto are hereinafter called the
“Exchange Act Reports”. The Exchange Act Reports, when they were or are filed with the Commission, conformed or will conform in all material respects to the applicable requirements of the Exchange Act and the applicable rules and
regulations of the Commission thereunder; and no such documents were filed with the Commission since the Commission’s close of business on the business day immediately prior to the date of this Agreement and prior to the execution of this
Agreement, except as set forth on Schedule II(a) hereof. The Preliminary Offering Circular or the Offering Circular and any amendments or supplements thereto and the Exchange Act Reports did not and will not, as of their respective dates, contain an
untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this
representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by a Purchaser through the Representatives expressly for use therein; 

(b) For the purposes of this Agreement, the “Applicable Time” is 7:00 a.m. (Eastern time) on the next business
day following the date of this Agreement; the Pricing Circular as supplemented by the information set forth in Schedule IV hereto, taken together (collectively, the “Pricing Disclosure Package”) as of the Applicable Time, did not include
any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Company Supplemental Disclosure
Document (as defined in Section 6(a)(i)) listed on Schedule II(b) hereto does not conflict with the information contained in the Pricing Circular or the Offering Circular and each such Company Supplemental Disclosure Document, as
supplemented by and taken together with the Pricing Disclosure Package as of the Applicable Time, did not include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to statements or omissions made in a Company Supplemental Disclosure Document in reliance upon and in
conformity with information furnished in writing to the Company by a Purchaser through the Representatives expressly for use therein; 
  

 2 

 (c) Neither the Company nor any of its subsidiaries has sustained since the
date of the latest audited financial statements included in the Pricing Circular any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or
court or governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Circular; and, since the respective dates as of which information is given in the Pricing Circular, there has not been any change in the
capital stock or long-term debt of the Company or any of its subsidiaries (except for the vesting or exercise of restricted stock units or options pursuant to equity incentive, compensation or benefit plans in existence on the date of this
Agreement) or any material adverse change, or any development involving a prospective material adverse change, in or affecting the general affairs, management, consolidated financial position, stockholders’ equity or results of operations of
the Company and its subsidiaries, taken as a whole, otherwise than as set forth or contemplated in the Pricing Circular; 

(d) The Company and the subsidiaries of the Company set forth on Schedule III hereto (each a “Subsidiary” and,
collectively, the “Subsidiaries”) have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them, in each case free and clear of all liens, encumbrances and defects
except such as are described in the Pricing Circular or such as would not have a material adverse effect on the general affairs, management, consolidated financial position, stockholders’ equity, results of operations or prospects of the
Company and its subsidiaries, taken as a whole (a “Material Adverse Effect”); and any real property and buildings held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with
such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries; 

(e) The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the
State of Delaware, with power and authority (corporate and other) to own its properties and conduct its business as described in the Pricing Circular, and has been duly qualified as a foreign corporation for the transaction of business and is in
good standing (to the extent such concept exists) under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except where the failure to be in good standing (with
respect to each other jurisdiction only) or duly qualified would not have a Material Adverse Effect; and each Subsidiary has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited
liability company, as the case may be, in good standing (to the extent such concept exists) under the laws of its jurisdiction of incorporation or organization, as the case may be; 

(f) The Company has full corporate right, power, and authority to execute and deliver this Agreement and the Indenture
(collectively, the “Transaction Documents”), and to perform its obligations thereunder; and all actions required to be taken for the due 

 

 3 

 
and proper authorization, execution and delivery by it of this Agreement and the Indenture and the consummation by it of the transactions contemplated thereunder have been, or will be prior to
the First Time of Delivery, duly and validly taken; the Indenture has been duly executed and delivered by the Company; 

(g) The Company has an authorized capitalization as set forth in the Pricing Circular, and all of the issued shares of
capital stock of the Company have been duly authorized and validly issued, are fully paid and non-assessable and conform in all material respects to the description of the Stock contained in the Pricing Circular; and all of the issued shares of
capital stock of each Subsidiary of the Company have been duly authorized and validly issued, are fully paid and non-assessable and (except for directors’ qualifying shares) are owned directly or indirectly by the Company, free and clear of all
liens, encumbrances, equities or claims (except for those related to the Credit Agreement, dated as of August 22, 2006, as amended to date, among the Company, as Borrower, the several lenders from time to time parties thereto, and Bank of
America, N.A., as Administrative Agent); 
 (h) The Indenture has been duly authorized by the Company and duly
qualified under the Trust Indenture Act of 1939, as amended, and, when duly executed and delivered by the Company and the Trustee, will constitute a valid and binding agreement of the Company, enforceable against the Company in accordance with its
terms, except as the enforcement thereof may be limited by bankruptcy, insolvency (including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting enforcement of creditors’ rights
generally and except as enforcement thereof is subject to general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law); 

(i) The Securities have been duly authorized and, at the Time of Delivery, will have been duly executed by the Company
and, when authenticated, issued and delivered in the manner provided for in the Indenture and the Securities and delivered against payment of the purchase price therefor as provided in this Agreement, will constitute valid and binding obligations of
the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency (including, without limitation, all laws relating to fraudulent transfers), reorganization,
moratorium or similar laws affecting enforcement of creditors’ rights generally and except as enforcement thereof is subject to general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law),
and will be in the form contemplated by, and entitled to the benefits of, the Indenture; 
 (j) The Underlying
Common Stock conforms in all material respects to the description of the Stock contained or incorporated by reference in the Pricing Circular. Upon issuance and delivery of the Securities in accordance with this Agreement and the Indenture, and
assuming the Indenture and the Securities are valid and binding agreements, the Securities will be convertible at the option of the holder thereof for shares of Underlying Common Stock in accordance with the terms of the Securities and the
Indenture; the shares of the Underlying Common Stock have been duly authorized 
  

 4 

 
and reserved for issuance upon such conversion, in accordance with the terms of the Indenture and the Securities, by all necessary corporate action and such shares, when issued upon conversion,
will be validly issued and will be fully paid and non-assessable, and the issuance of such shares upon such conversion will not be subject to the preemption or other similar rights of any security holder of the Company; 

(k) The compliance by the Company with all of the provisions of the Transaction Documents and the consummation of the
transactions therein contemplated will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (i) any indenture, mortgage, deed of trust, loan agreement or other agreement or
instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries is subject, (ii) the
provisions of the Certificate of Incorporation or By-laws of the Company or (iii) any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its Subsidiaries or any of
their properties except, in the case of clauses (i) and (iii), for such breaches, violations or defaults that would not result in a Material Adverse Effect; and no consent, approval, authorization, order, registration or qualification of or
with any such court or governmental agency or body is required for the issue and sale of the Securities or the consummation by the Company of the transactions contemplated by the Transaction Documents, except such consents, approvals,
authorizations, registrations or qualifications as may be required under state securities (including insurance securities) or Blue Sky laws in connection with the purchase and distribution of the Securities by the Purchasers or have been obtained or
made; 
 (l) Neither the Company nor any of its Subsidiaries is in violation of its Certificate of Incorporation
or By-laws or in default in the performance or observance of any material obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party
or by which it or any of its properties may be bound; 
 (m) The statements set forth in the Pricing Circular
under the caption “Description of Notes,” insofar as they purport to constitute a summary of the terms of the Securities, under the caption “Description of the Convertible Note Hedge and Warrant Transactions,” insofar as they
purport to describe the provisions of the agreements referred to therein, and under the caption “Certain United States Federal Income Tax Considerations,” in so far as they purport to describe the provisions of the laws referred to
therein, and under the caption “Plan of Distribution,” insofar as they purport to describe the provisions of the agreements referred to therein, are accurate, complete and fair in all material respects; 

(n) Other than as set forth in the Pricing Circular, there are no legal or governmental proceedings pending to which the
Company or any of its Subsidiaries is a party or of which any property of the Company or any of its Subsidiaries is the subject which could be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect; and, to the
knowledge of the Company, no such proceedings are threatened or contemplated by governmental authorities or threatened by others; 
  

 5 

 (o) When the Securities are issued and delivered pursuant to this Agreement,
the Securities will not be of the same class (within the meaning of Rule 144A under the Securities Act) as securities which are listed on a national securities exchange registered under Section 6 of the Exchange Act or quoted in a U.S.
automated inter-dealer quotation system; 
 (p) The Company is subject to Section 13 of the Exchange Act;

 (q) Neither the Company nor, to its knowledge, any person acting on its behalf has offered or sold the
Securities by means of any general solicitation or general advertising within the meaning of Rule 502(c) under the Act; 

(r) Within the preceding six months, neither the Company nor any other person acting on behalf of the Company has offered
or sold to any person any Securities, or any securities of the same or a similar class as the Securities, other than Securities offered or sold to the Purchasers hereunder; 

(s) The Company and its Subsidiaries possess such permits, licenses, approvals, consents and other authorizations
(collectively, “Governmental Licenses”) issued by the appropriate federal, state, local or foreign regulatory agencies or bodies necessary to conduct the business now operated by them, except where the failure to possess such Governmental
Licenses would not have a Material Adverse Effect; the Company and its Subsidiaries are in compliance with the terms and conditions of all such Governmental Licenses, except where the failure so to comply would not, individually or in the aggregate,
have a Material Adverse Effect; all of the Governmental Licenses are valid and in full force and effect, except where the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not
have a Material Adverse Effect; and neither the Company nor any of its Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such Governmental Licenses; 

(t) The Company and its Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are customary in the businesses in which they are engaged, except where the failure to be so insured would not have a Material Adverse Effect, and neither the Company nor any of its Subsidiaries has any reason to
believe that any of them will not be able to (i) renew its existing insurance coverage as and when such coverage expires except where the failure to renew would not have a Material Adverse Effect, or (ii) to obtain similar coverage from
similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect; 

(u) The Company and its Subsidiaries own, possess, have other rights to use or can acquire on reasonable terms, adequate
patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable 

 

 6 

 
proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property (collectively, “Intellectual Property”) necessary
to carry on the business now operated by them, except where the failure to own, possess or have other rights to use, or be able to acquire, such Intellectual Property would not have a Material Adverse Effect; neither the Company nor any of its
Subsidiaries has received any notice or is otherwise aware of any infringement of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or circumstances which would render any Intellectual Property
invalid or inadequate to protect the interest of the Company or any of its Subsidiaries therein, which infringement, conflict, invalidity or inadequacy, individually or in the aggregate, would be reasonably likely to have a Material Adverse Effect;

 (v) The Company is not and, after giving effect to the offering and sale of the Securities and the application
of the proceeds thereof, will not be an “investment company,” as such term is defined in the Investment Company Act of 1940, as amended; 

(w) Neither the Company nor any of its affiliates does business with the government of Cuba or, to the Company’s
knowledge, with any person or affiliate located in Cuba within the meaning of Section 517.075, Florida Statutes; 

(x) The Company and each of its Subsidiaries maintain a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of consolidated financial statements in
conformity with United States generally accepted accounting principles and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the
recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; 

(y) The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and
15d-15(e) under the Exchange Act); such disclosure controls and procedures are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company’s principal executive
officer and its principal financial officer by others within those entities and are effective to perform the functions for which they were established; 

(z) There has been no change in the Company’s internal control over financial reporting since March 31, 2010
that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and, since December 31, 2009, the audit committee of the board of directors of the Company has been
advised by the Company of (i) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record,
process, summarize and report financial information and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting;

  

 7 

 (aa) The consolidated financial statements, together with related schedules
and notes, included or incorporated by reference in the Pricing Circular (and any amendment or supplement thereto) present fairly in all material respects the financial position, results of operations and changes in financial position of the Company
and its consolidated subsidiaries at the respective dates or for the respective periods to which they apply; such statements and related schedules and notes have been prepared in accordance with United States generally accepted accounting principles
consistently applied throughout the periods involved, except as disclosed therein; and the other financial and statistical information and data of the Company set forth in the Pricing Circular (and any amendment or supplement thereto) present
fairly, in all material respects, the information stated therein and have been derived from the books and records of the Company, and such other financial information and data have been prepared on a basis consistent with such financial statements;

 (bb) PricewaterhouseCoopers LLP (“PWC”), which has certified certain financial statements of the
Company and its subsidiaries, is an independent registered public accounting firm with respect to the Company within the meaning of the Act and the applicable rules and regulations thereunder adopted by the Commission and the Public Company
Accounting Oversight Board; 
 (cc) Each subsidiary of the Company which is engaged in the business of acting as
a broker-dealer or an investment advisor (respectively, a “Broker-Dealer Subsidiary” and an “Investment Advisor Subsidiary”) is duly licensed or registered as a broker-dealer or investment advisor, as the case may be, in each
jurisdiction where it is required to be so licensed or registered to conduct its business, except where the failure to be so licensed or registered would not have a Material Adverse Effect; each Broker-Dealer Subsidiary and each Investment Advisor
Subsidiary has all other necessary approvals of and from all applicable regulatory authorities, including any self-regulatory organization, to conduct its businesses, except where the failure to have such approvals would not have a Material Adverse
Effect; except as otherwise provided in the Pricing Circular, none of the Broker-Dealer Subsidiaries or Investment Advisor Subsidiaries has received any notification from any applicable regulatory authority to the effect that any additional
approvals from such regulatory authority are needed to be obtained by such subsidiary and have not been obtained, in any case where it could be reasonably expected that the Broker-Dealer Subsidiary will be unable to obtain such additional approvals
and the failure to obtain any such additional approvals would require such Subsidiary to cease or otherwise materially limit the conduct of its business; and each Broker-Dealer Subsidiary and each Investment Advisor Subsidiary is in compliance with
the requirements of the broker-dealer and investment advisor laws and regulations of each jurisdiction that are applicable to such Subsidiary, and has filed all notices, reports, documents or other information required to be filed thereunder, in
each case with such exceptions as would not have, individually or in the aggregate, a Material Adverse Effect; 

(dd) The Company will not take, directly or indirectly, any action designed to cause or result in, or that has constituted
or might reasonably be expected to constitute, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any securities of the Company to facilitate the sale or resale of the Notes; 

 

 8 

 (ee) There is and has been no failure on the part of the Company or any of
the Company’s directors or officers, in their capacities as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (the
“Sarbanes-Oxley Act”), including Section 402 related to loans and Sections 302 and 906 related to certifications; 

(ff) None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent,
employee or affiliate of the Company or any of its subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and
regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the
payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any
candidate for foreign political office, in contravention of the FCPA, and the Company, its subsidiaries and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain
policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith; 

(gg) To the knowledge of the Company, the operations of the Company and its subsidiaries are and have been conducted at
all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable
jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action,
suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company,
threatened; and 
 (hh) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any
director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and
the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds, to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the
activities of any person currently subject to any U.S. sanctions administered by OFAC. 
 2. Subject to the terms and conditions
herein set forth, (a) the Company agrees to sell to each of the Purchasers, and each of the Purchasers agrees, severally and not jointly, to purchase from the Company the Initial Securities at a price equal to 97.0% of the principal amount
thereof and (b) in the event and to the extent that the Purchasers shall exercise the election to purchase Optional Securities as provided below, the Company agrees to sell to each of the Purchasers, and each of the Purchasers agrees, severally
and not jointly, to purchase from the Company, at the purchase price set forth in clause (a) of this Section 2, that portion of the aggregate principal amount of Optional Securities as to which such election shall have been exercised.

  

 9 

 The Company hereby grants to the Purchasers the right to purchase at their election up to
$15,000,000 aggregate principal amount of Optional Securities at the purchase price set forth in the paragraph above solely to cover over-allotments, if any. Any such election to purchase Optional Securities may be exercised only by written notice
from you to the Company, given within a period of 30 calendar days after the date of this Agreement and setting forth the aggregate principal amount of Optional Securities to be purchased and the date on which such Optional Securities are to be
delivered, as determined by you but in no event earlier than the First Time of Delivery (as defined in Section 4 hereof) or, unless you and the Company otherwise agree in writing, earlier than two or later than ten business days after the date
of such notice. 
 3. Upon the authorization by you of the release of the Securities, the several Purchasers propose to offer
the Securities for sale upon the terms and conditions set forth in this Agreement and the Pricing Circular and each Purchaser hereby represents and warrants to, and agrees with the Company that: 

(a) It will offer and sell the Securities only to persons who it reasonably believes are “qualified institutional
buyers” (“QIBs”) within the meaning of Rule 144A under the Act in transactions meeting the requirements of Rule 144A; 

(b) It is a QIB and an accredited investor within the meaning of Rule 501 under the Act; and 

(c) It will not offer or sell the Securities by any form of general solicitation or general advertising, including but not
limited to the methods described in Rule 502(c) under the Act. 
 4. (a) The Securities to be purchased by each Purchaser
hereunder will be represented by one or more definitive global Securities in book-entry form which will be deposited by or on behalf of the Company with The Depository Trust Company (“DTC”) or its designated custodian. The Company will
deliver the Securities to Goldman, Sachs & Co., for the account of each Purchaser, against payment by or on behalf of such Purchaser of the purchase price therefor by wire transfer in Federal (same day) funds, by causing DTC to credit the
Securities to the account of Goldman, Sachs & Co. at DTC. The Company will cause the certificates representing the Securities to be made available to Goldman, Sachs & Co. for checking at least twenty-four hours prior to the Time of
Delivery (as defined below) at the office of Dewey & LeBoeuf LLP: 1301 Avenue of the Americas, New York, New York, 10019 (the “Closing Location”) The time and date of delivery and payment for the Securities shall be, with
respect to the Initial Securities, 9:30 a.m., New York time, on June 15, 2010, or such other time and date as the Representatives and the Company may agree upon in writing, and, with respect to the Optional Securities, 9:30 a.m., New York time,
on the date specified by the Representatives in the written notice given by the Representatives of the Purchasers’ election to purchase such Optional Securities, or such other time and date as the Representatives and the Company may agree upon
in writing. Such time and date for delivery of the Initial Securities is herein called 
  

 10 

 
the “First Time of Delivery,” such time and date for delivery of the Optional Securities, if not the First Time of Delivery, is herein called the “Second Time of Delivery,”
and each such time and date for delivery is herein called a “Time of Delivery.” 
 (b) The documents to
be delivered at each Time of Delivery by or on behalf of the parties hereto pursuant to Section 8 hereof, including the cross receipt for the Securities and any additional documents requested by the Purchasers pursuant to Section 8(k)
hereof will be delivered at the offices of Dewey & LeBoeuf LLP, 1301 Avenue of the Americas, New York, New York 10019 (the “Closing Location”). For the purposes of this Section 4, “New York Business Day” shall mean
each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York are generally authorized or obligated by law or executive order to close. 

5. The Company agrees with each of the Purchasers: 

(a) To prepare the Offering Circular in a form approved by you; to make no amendment or any supplement to the Offering
Circular which shall be disapproved by you promptly after reasonable notice thereof; and to furnish you with copies thereof; 

(b) Promptly from time to time to take such action as you may reasonably request to qualify the Securities and the
Underlying Common Stock for offering and sale under the securities laws of such jurisdictions as you may reasonably request and to comply with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long
as may be necessary to complete the distribution of the Securities and the Underlying Common Stock, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation or to file a general consent to service
of process in any jurisdiction or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject; 

(c) To furnish the Purchasers with written and electronic copies of the Offering Circular in New York City in such
quantities as you may reasonably request and if, at any time prior to the expiration of nine months after the date of the Offering Circular, any event shall have occurred as a result of which the Offering Circular as then amended or supplemented
would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Offering Circular is delivered, not
misleading, or, if for any other reason it shall be necessary or desirable during such same period to amend or supplement the Offering Circular, to notify you and upon your request to prepare and furnish without charge to each Purchaser and to any
dealer in securities as many written and electronic copies as you may from time to time reasonably request of an amended Offering Circular or a supplement to the Offering Circular which will correct such statement or omission or effect such
compliance; 
 (d) During the period beginning from the date hereof and continuing to and including the date 90
days after the date hereof, not to offer, sell, pledge, contract to sell or otherwise dispose of, except as provided hereunder, any securities of the Company that are substantially similar to the Securities, including but not limited to any options
or 
  

 11 

 
warrants to purchase shares of Stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, shares of Stock or any such substantially similar
securities without the prior written consent of Goldman, Sachs & Co., except (x) pursuant to stock-based compensation, incentive or benefit plans and Company employee stock purchase plans existing on, or upon the conversion or exchange
of convertible or exchangeable securities outstanding as of, the date of this Agreement or (y) in connection with shares of the Stock issued or to be issued as consideration in connection with acquisitions; provided, that the
recipient of such shares of the Stock issued as consideration in an acquisition becomes a party to, and such shares of the Common Stock are subject to, the Second Amended and Restated Stockholders Agreement of the Company, dated as of
February 13, 2004, by and among the Company, Apollo Investment Fund IV, L.P. and certain of the other stockholders of the Company that are signatories thereto, as amended, (the “Stockholders Agreement”), the Lock-up Agreement by and
among the Company and certain of the other stockholders of the Company that are signatories thereto (the “Stockholder Lock-up Agreement”) or such other stockholders agreement of the Company containing restrictions on the transferability of
such shares of the Stock that are substantially similar to the provisions contained in the Stockholders Agreement or the Stockholder Lock-up Agreement; 

(e) Not to be or become, at any time prior to the expiration of two years after the Time of Delivery, an open-end
investment company, unit investment trust, closed-end investment company or face-amount certificate company that is or is required to be registered under Section 8 of the Investment Company Act; 

(f) At any time when the Company is not subject to Section 13 or 15(d) of the Exchange Act, for the benefit of
holders from time to time of Securities, to furnish at its expense, upon request, to holders of Securities and prospective purchasers of securities information (the “Additional Issuer Information”) satisfying the requirements of subsection
(d)(4)(i) of Rule 144A under the Act; 
 (g) In the event that such information is not publicly available on
EDGAR, to furnish to the holders of the Securities as soon as practicable after the end of each fiscal year an annual report (including a balance sheet and statements of income, stockholders’ equity and cash flows of the Company and its
consolidated subsidiaries certified by independent public accountants) and, as soon as practicable after the end of each of the first three quarters of each fiscal year (beginning with the fiscal quarter ending after the date of the Offering
Circular), to make available to its stockholders consolidated summary financial information of the Company and its subsidiaries for such quarter in reasonable detail; 

(h) During the period of one year after the Time of Delivery, the Company will not, and will not permit any of its
“affiliates” (as defined in Rule 144 under the Securities Act) to, resell any of the Securities which constitute “restricted securities” under Rule 144 that have been reacquired by any of them; 

 

 12 

 (i) To use the net proceeds received by it from the sale of the Securities
pursuant to this Agreement in the manner specified in the Pricing Circular under the caption “Use of Proceeds”; 

(j) Upon the reasonable request of any Purchaser, to furnish, or cause to be furnished, to such Purchaser an electronic
version of the Company’s trademarks, servicemarks and corporate logo for use on the website, if any, operated by the Purchaser for the purpose of facilitating the on-line offering of the Securities (the “License”); provided,
however, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred; 

(k) To reserve and keep available at all times, free of preemptive or other similar rights, a sufficient number of shares
of Stock, for the purpose of enabling the Company to satisfy any obligations to issue its Underlying Common Stock; and 

(l) To use its best efforts to list, subject to notice of issuance, the Underlying Common Stock on the New York Stock
Exchange. 
 6. (a) 

(i) The Company represents and agrees that, without the prior consent of the Representatives, it has not made and will not
make any offer relating to the Securities that, if the offering of the Securities contemplated by this Agreement were conducted as a public offering pursuant to a registration statement filed under the Act with the Commission, would constitute an
“issuer free writing prospectus,” as defined in Rule 433 under the Act (any such offer is hereinafter referred to as a “Company Supplemental Disclosure Document”); 

(ii) each Purchaser represents and agrees that, without the prior consent of the Company and the Representatives, other
than one or more term sheets relating to the Securities containing customary information and conveyed to purchasers of securities, it has not made and will not make any offer relating to the Securities that, if the offering of the Securities
contemplated by this Agreement were conducted as a public offering pursuant to a registration statement filed under the Act with the Commission, would constitute a “free writing prospectus,” as defined in Rule 405 under the Act (any such
offer (other than any such term sheets), is hereinafter referred to as a “Purchaser Supplemental Disclosure Document”); and 

(iii) any Company Supplemental Disclosure Document or Purchaser Supplemental Disclosure Document the use of which has been
consented to by the Company and the Representatives is listed on Schedule II(b) hereto. 
 7. The Company covenants and agrees
with the several Purchasers that the Company will pay or cause to be paid the following: (i) the fees, disbursements and expenses of the Company’s counsel and accountants in connection with the issue of the Securities and the Underlying
Common Stock and all other expenses in connection with the preparation, printing 
  

 13 

 
and filing of the Preliminary Offering Circular and the Offering Circular and any amendments and supplements thereto, and the mailing and delivering of copies thereof to the Purchasers and
dealers; (ii) the cost of printing or producing this Agreement, the Blue Sky Memorandum, closing documents (including any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the
Securities and the Underlying Common Stock; (iii) all expenses in connection with the qualification of the Securities and the Underlying Common Stock for offering and sale under state securities laws in accordance with this Agreement, including
the reasonable fees and disbursements of counsel to the Purchasers in connection with such qualification and in connection with the Blue Sky survey; (iv) the filing fees incident to, and the fees and disbursements of counsel to the Purchasers
in connection with, securing any required review by the Financial Industry Regulatory Authority, Inc. of the terms of the sale of the Securities and the Underlying Common Stock; (v) the cost of preparing stock certificates; (vi) the cost
and charges of any transfer agent, registrar or dividend disbursing agent; (vii) the fees and expenses of the Trustee and any agent of the Trustee and the fees and disbursements of counsel for the Trustee in connection with the Indenture and
the Securities; (viii) all fees and expenses in connection with listing the Underlying Common Stock on the New York Stock Exchange; and (viii) all other costs and expenses incident to the performance of its obligations hereunder which are
not otherwise specifically provided for in this Section. 
 8. The obligations of the Purchasers hereunder, as to the Securities
to be delivered at each Time of Delivery, shall be subject, in their discretion, to the condition that all representations and warranties and other statements of the Company herein are, at and as of such Time of Delivery, true and correct, the
condition that the Company shall have performed all of its obligations hereunder theretofore to be performed, and the following additional conditions: 

(a) Dewey & LeBoeuf LLP, counsel to the Purchasers, shall have furnished to you such written opinion or opinions
(a draft of each such opinion is attached as Exhibit B-1 hereto), dated such Time of Delivery, and a written letter dated such Time of Delivery (a draft of which is attached as Exhibit B-2 hereto) in a form or forms acceptable to you, and such
counsel shall have received such papers and information as they may reasonably request to enable them to pass upon such matters; 

(b) Latham & Watkins, LLP, counsel to the Purchasers, shall have furnished to you such written opinion or
opinions (a draft of each such opinion is attached as Exhibit C hereto), dated such Time of Delivery, in a form or forms acceptable to you, and such counsel shall have received such papers and information as they may reasonably request to enable
them to pass upon such matters; 
 (c) Skadden, Arps, Slate, Meagher & Flom LLP, counsel to the Company,
shall have furnished to you their written opinions, dated such Time of Delivery, in form and substance satisfactory to you, to the effect set forth in Exhibits D-1 and D-2 hereto and a written letter, dated such Time of Delivery, in form and
substance satisfactory to you, to the effect set forth in Exhibit D-3 hereto; 
 (d) Stancil E. Barton, Executive
Vice President, General Counsel and Corporate Secretary of the Company, shall have furnished to you his written opinion, dated such Time of Delivery, in form and substance satisfactory to you, to the effect set forth in Exhibit E hereto; 

 

 14 

 (e) On the date of the Offering Circular prior to the execution of this
Agreement and also at each Time of Delivery, PWC shall have furnished to you a letter or letters, dated the respective dates of delivery thereof, in form and substance satisfactory to you, to the effect set forth in Annex II hereto (the executed
copy of the letter delivered prior to the execution of this Agreement is attached as Annex II(a) hereto and a draft of the form of letter to be delivered as of each Time of Delivery is attached as Annex II(b) hereto); 

(f)(i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial
statements included in the Pricing Circular any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree,
otherwise than as set forth or contemplated in the Pricing Circular, and (ii) since the respective dates as of which information is given in the Pricing Circular there shall not have been any change in the capital stock or long-term debt of the
Company or any of its subsidiaries (except for the vesting or exercise of restricted stock units or options pursuant to equity incentive, compensation or benefit plans in existence on the date of this Agreement or with respect to issuance of the
Notes) or any change, or any development involving a prospective change, in or affecting the general affairs, management, financial position, stockholders’ equity or results of operations of the Company and its subsidiaries, otherwise than as
set forth or contemplated in the Pricing Circular, the effect of which, in any such case described in clause (i) or (ii), is in the judgment of the Representatives so material and adverse as to make it impracticable or inadvisable to proceed
with the offering or the delivery of the Securities being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Circular; 

(g) On or after the Applicable Time of Sale (i) no downgrading shall have occurred in the rating accorded the
Company’s debt securities, if any, by any “nationally recognized statistical rating organization,” as that term is defined by the Commission for purposes of Rule 436(g)(2) under the Act, and (ii) no such organization shall have
publicly announced that it has under surveillance or review, with possible negative implications, its rating, if any, of any of the Company’s debt securities; 

(h) On or prior to the Time of Delivery, the Underlying Common Stock shall have been approved for listing on the New York
Stock Exchange, subject to official notice of issuance; 
 (i) On or after the Applicable Time of Sale there
shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange; (ii) a suspension or material limitation in trading in the Company’s securities
on the New York Stock Exchange; (iii) a general moratorium on commercial banking activities declared by either Federal or New York State authorities or a material disruption in commercial banking or securities settlement or

  

 15 

 
clearance services in the United States; (iv) the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or
(v) the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv) or (v) in the judgment of the
Representatives makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Securities being delivered at such Time of Delivery on the terms and in the manner contemplated in the Offering Circular; 

(j) The Company shall have obtained and delivered to the Purchasers executed copies of an agreement from each of the
Company’s officers and directors substantially to the effect set forth in Exhibit F hereto with respect to such officer or director, in form and substance satisfactory to you; 

(k) The Company shall have furnished or caused to be furnished to you at such Time of Delivery certificates of officers of
the Company satisfactory to you as to the accuracy of the representations and warranties of the Company herein at and as of such Time of Delivery, as to the performance by the Company of all of its obligations hereunder to be performed at or prior
to such Time of Delivery, and as to such other matters as you may reasonably request, and the Company shall have furnished or caused to be furnished certificates as to the matters set forth in subsection (f) of this Section. 

9. (a) The Company will indemnify and hold harmless each Purchaser against any losses, claims, damages or liabilities, to which such
Purchaser may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact
contained in any Preliminary Offering Circular, the Pricing Circular, the Offering Circular, or any amendment or supplement thereto, the Pricing Disclosure Package, or in any Company Supplemental Disclosure Document, or arise out of or are based
upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each Purchaser for any legal or other expenses reasonably incurred by
such Purchaser in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim,
damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in any Preliminary Offering Circular, the Pricing Circular, the Offering Circular, or any amendment or supplement
thereto, the Pricing Disclosure Package, or in any Company Supplemental Disclosure Document in reliance upon and in conformity with written information furnished to the Company by any Purchaser through the Representatives expressly for use therein.

 (b) Each Purchaser will indemnify and hold harmless the Company against any losses, claims, damages or
liabilities to which the Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of
a material fact contained in any Preliminary Offering Circular, the 
  

 16 

 
Pricing Circular, the Offering Circular, or any amendment or supplement thereto, the Pricing Disclosure Package, or in any Company Supplemental Disclosure Document, or arise out of or are based
upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or
alleged untrue statement or omission or alleged omission was made in any Preliminary Offering Circular, the Pricing Circular, the Offering Circular, or any amendment or supplement thereto, the Pricing Disclosure Package, or in any Company
Supplemental Disclosure Document, in reliance upon and in conformity with written information furnished to the Company by such Purchaser through the Representatives expressly for use therein; and will reimburse the Company for any legal or other
expenses reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. 

(c) Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice of the
commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; but the omission so to
notify the indemnifying party shall not relieve it from any liability which it may have to any indemnified party otherwise than under such subsection. In case any such action shall be brought against any indemnified party and it shall notify the
indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with
a single counsel (in addition to local counsel) satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such
indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal expenses of other counsel or any other expenses, in each case subsequently
incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of investigation. No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or
consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such
action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as to or an
admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. 
 (d) If the
indemnification provided for in this Section 9 is unavailable to or insufficient to hold harmless an indemnified party under subsection (a) or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect
thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is
appropriate to reflect the relative benefits received by the Company on the one hand and the Purchasers on the other from the offering of the Securities. If, however, the allocation provided by the immediately

  

 17 

 
preceding sentence is not permitted by applicable law or if the indemnified party failed to give the notice required under subsection (c) above, then each indemnifying party shall contribute
to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Purchasers on the other in connection with
the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the
Purchasers on the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Purchasers,
in each case as set forth in the Offering Circular. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material
fact relates to information supplied by the Company on the one hand or the Purchasers on the other and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company
and the Purchasers agree that it would not be just and equitable if contributions pursuant to this subsection (d) were determined by pro rata allocation (even if the Purchasers were treated as one entity for such purpose) or by any other
method of allocation which does not take account of the equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in
respect thereof) referred to above in this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this subsection (d), no Purchaser shall be required to contribute any amount in excess of the amount by which the total price at which the Securities underwritten by it and distributed to the public were offered to
the public exceeds the amount of any damages which such Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Purchasers’ obligations in this subsection (d) to contribute are several in proportion
to their respective underwriting obligations and not joint. 
 (e) The obligations of the Company under this
Section 9 shall be in addition to any liability which the Company may otherwise have and shall extend, upon the same terms and conditions, to each person, if any, who controls (within the meaning of Section 15 of the Act) any Purchaser, or
any of the respective partners, directors, officers and employees of any Purchaser or any such controlling person; and the obligations of the Purchasers under this Section 9 shall be in addition to any liability which the respective Purchasers
may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company and to each person, if any, who controls the Company within the meaning of the Act. 

 

 18 

 10. (a) If any Purchaser shall default in its obligation to purchase the Securities
which it has agreed to purchase hereunder at a Time of Delivery, you may in your discretion arrange for you or another party or other parties to purchase such Securities on the terms contained herein. If within thirty-six hours after such default by
any Purchaser you do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period of thirty-six hours within which to procure another party or other parties reasonably satisfactory to you to purchase such
Securities on such terms. In the event that, within the respective prescribed periods, you notify the Company that you have so arranged for the purchase of such Securities, or the Company notifies you that it has so arranged for the purchase of such
Securities, you, and the Company shall have the right to postpone a Time of Delivery for a period of not more than seven days, in order to effect whatever changes may thereby be made necessary in the Offering Circular, or in any other documents or
arrangements, and the Company agrees to prepare promptly any amendments to the Offering Circular which in your opinion may thereby be made necessary. The term “Purchaser” as used in this Agreement shall include any person substituted under
this Section with like effect as if such person had originally been a party to this Agreement with respect to such Securities. 

(b) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Purchaser or Purchasers
by you, and the Company as provided in subsection (a) above, the aggregate principal amount of such Securities which remains unpurchased does not exceed one-eleventh of the aggregate principal amount of all the Securities to be purchased at
such Time of Delivery, then the Company shall have the right to require each non-defaulting Purchaser to purchase the number of Securities which such Purchaser agreed to purchase hereunder at such Time of Delivery and, in addition, to require each
non-defaulting Purchaser to purchase its pro rata share (based on the principal amount of Securities which such Purchaser agreed to purchase hereunder) of the Securities of such defaulting Purchaser or Purchasers for which such arrangements have not
been made; but nothing herein shall relieve a defaulting Purchaser from liability for its default. 
 (c) If,
after giving effect to any arrangements for the purchase of the Securities of a defaulting Purchaser or Purchasers by you, and the Company as provided in subsection (a) above, the aggregate principal amount of such Securities which remains
unpurchased exceeds one-eleventh of the aggregate principal amount of all of the Securities to be purchased at such Time of Delivery, or if the Company shall not exercise the right described in subsection (b) above to require non-defaulting
Purchasers to purchase Securities of a defaulting Purchaser or Purchasers, then this Agreement (or, with respect to the Second Time of Delivery, the obligations of the Purchasers to purchase and of the Company to sell the Optional Securities) shall
thereupon terminate, without liability on the part of any non-defaulting Purchaser or the Company, except for the expenses to be borne by the Company and the Purchasers as provided in Section 7 hereof and the indemnity and contribution
agreements in Section 9 hereof; but nothing herein shall relieve a defaulting Purchaser from liability for its default. 

11. The respective indemnities, agreements, representations, warranties and other statements of the Company and the several Purchasers,
as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any
Purchaser or any controlling person of any Purchaser, or the Company, or any officer or director or controlling person of the Company, and shall survive delivery of and payment for the Securities. 

 

 19 

 12. If for any reason any Securities are not delivered by or on behalf of the Company as
provided herein, the Company will reimburse the Purchasers through you for all out-of-pocket expenses approved in writing by you, including fees and disbursements of counsel, reasonably incurred by the Purchasers in making preparations for the
purchase, sale and delivery of the Securities not so delivered, but the Company shall then be under no further liability to any Purchaser in respect of the Securities not so delivered except as provided in Sections 7 and 9 hereof. 

13. In all dealings hereunder, you shall act on behalf of each of the Purchasers, and the parties hereto shall be entitled to act and
rely upon any statement, request, notice or agreement on behalf of any Purchaser made or given by you jointly. 
 All
statements, requests, notices and agreements hereunder shall be in writing, and if to the Purchasers, shall be delivered or sent by mail, telex or facsimile transmission to you as the Representatives in care of (i) Goldman, Sachs &
Co., 200 West Street, New York, New York 10282, Attention: Registration Department; and (ii) Merrill Lynch, Pierce, Fenner & Smith Incorporated, One Bryant Park, New York, New York 10036, Attention: Syndicate Department, with a copy to
ECM Legal; and if to the Company shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company set forth in the Offering Circular, Attention: General Counsel; provided, however, that any notice to a
Purchaser pursuant to Section 9(c) hereof shall be delivered or sent by mail, telex or facsimile transmission to such Purchaser at its address set forth in its Purchasers’ Questionnaire or telex constituting such Questionnaire, which
address will be supplied to the Company by you on request. Any such statements, requests, notices or agreements shall take effect upon receipt thereof. 

In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the
Purchasers are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will
allow the Purchasers to properly identify their respective clients. 
 14. This Agreement shall be binding upon, and inure
solely to the benefit of, the Purchasers and the Company and, to the extent provided in Sections 9 and 11 hereof, the officers and directors of the Company and each person who controls (within the meaning of Section 15 of the Act) the Company,
any Purchaser, or any of the respective partners, directors, officers, employees and agents of the Purchasers or any such controlling person of a Purchaser, and their respective heirs, executors, administrators, successors and assigns, and no other
person shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Securities from any Purchaser shall be deemed a successor or assign by reason merely of such purchase. 

15. Time shall be of the essence of this Agreement. As used herein, the term “business day” shall mean any day when the
Commission’s office in Washington, D.C. is open for business. 
  

 20 

 16. This Agreement shall be governed by and construed in accordance with the laws of the
State of New York. 
 17. This Agreement may be executed by any one or more of the parties hereto in any number of counterparts,
each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. 

18. The Company is authorized, subject to applicable law, to disclose any and all aspects of this potential transaction that are
necessary to support any U.S. federal income tax benefits expected to be claimed with respect to such transaction, and all materials of any kind (including tax opinions and other tax analyses) related to those benefits, without the Purchasers
imposing any limitation of any kind. 
 19. The Company acknowledges and agrees that, in connection with the purchase and sale
of the Securities pursuant to this Agreement, (i) the purchase and sale of the Securities pursuant to this Agreement, including the determination of the offering price of the Securities and any related discounts and commissions, is an
arm’s length commercial transaction between the Company on the one hand, and the several Purchasers, on the other hand, (ii) and in connection with the process leading to such transaction, each Purchaser is and has been acting solely as a
principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii) no Purchaser has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect
to the offering contemplated hereby or the process leading thereto (irrespective of whether such Purchaser has advised or is currently advising the Company on other matters) and no Purchaser has any obligation to the Company with respect to the
offering contemplated hereby except the obligations expressly set forth in this Agreement, (iv) the Purchasers and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the
Company, and (v) the Purchasers have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the
extent it deemed appropriate. 
 This Agreement supersedes all prior agreements and understandings (whether written or oral)
between the Company and the Purchasers with respect to the subject matter hereof. 
 The Company and the Purchasers hereby each
irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. 

If the foregoing is in accordance with your understanding, please sign and return to us six counterparts hereof, and upon the acceptance
hereof by you, on behalf of each of the Purchasers, this letter and such acceptance hereof shall constitute a binding agreement among each of the Purchasers and the Company. It is understood that your acceptance of this letter on behalf of each of
the Purchasers is pursuant to the authority set forth in a form of Agreement among Purchasers, the form of which shall be submitted to the Company for examination, upon request, but without warranty on your part as to the authority of the signers
thereof. 
  

 21 

			
	Very truly yours,
	
	National Financial Partners Corp.
		
	By:	 	 /s/ Donna J. Blank

	Name:	 	Donna J. Blank
	Title:	 	 Executive Vice President and

Chief Financial Officer

  

 22 

			
	Accepted as of the date hereof
	
	Goldman, Sachs & Co.
		
	By:	 	 /s/ Goldman, Sachs & Co

Merrill Lynch, Pierce, Fenner & Smith Incorporated 

			
		
	By:	 	 /s/ Scott Littlejohn

On behalf of each of the Purchasers 

 SCHEDULE I 

 

							
	 Purchaser
	  	Aggregate
Amount of
Initial
Securities to be
Purchased	  	Aggregate
Amount
of
Optional
Securities
to be Purchased
if Maximum
Option
Exercised
	 Goldman, Sachs & Co.
	  	$	62,500,000	  	$	7,500,000
	 Merrill Lynch, Pierce, Fenner & Smith Incorporated
	  	 	37,500,000	  	 	4,500,000
	 Wells Fargo Securities, LLC
	  	 	12,500,000	  	 	1,500,000
	 RBS Securities, Inc.
	  	 	6,250,000	  	 	750,000
	 U.S. Bancorp Investments, Inc.
	  	 	6,250,000	  	 	750,000
		  	 	 	  	 	 
	 Total
	  	$	125,000,000	  	$	15,000,000
		  	 	 	  	 	 

  

 I-1 

 SCHEDULE II 

 

	(a)	Additional Documents Incorporated by Reference: 

The Company’s Current Report on Form 8-K, filed with the Commission on June 9, 2010 

The Company’s Schedule TO, filed with the Commission on June 9, 2010 

 

	(b)	Approved Supplemental Disclosure Documents: 

None 

 SCHEDULE III 

List of Subsidiaries (as defined in Section 1(d) 

NFP Insurance Services, Inc. 
 NFP Securities,
Inc. 
 Massachusetts Business Association, L.L.C. 

 SCHEDULE IV 

The term sheet attached to this Agreement as Annex I. 

 Exhibit B-1 

[Opinion of Dewey & LeBoeuf LLP] 
  

 B-1 

 Exhibit B-2 

[Negative Assurance Letter of Dewey & LeBoeuf LLP] 

 

 B-2 

 Exhibit C 

[Opinion of Latham & Watkins LLP] 
  

 C-1 

 Exhibit D-1 

[Opinion of Skadden, Arps, Slate, Meagher & Flom LLP] 

 

 D-1 

 Exhibit D-2 

[Tax Opinion of Skadden, Arps, Slate, Meagher & Flom LLP] 

 

 D-2 

 Exhibit D-3 

[Negative Assurance Letter of Skadden, Arps, Slate, Meagher & Flom LLP] 

 

 D-3 

 Exhibit E 

[Opinion of Stancil E. Barton] 
  

 E-1 

 Exhibit F 

National Financial Partners Corp. 

Form of Lock-Up Agreement 

June     , 2010 

Goldman, Sachs & Co. 
 200 West Street

 New York, New York 10282 
 Merrill
Lynch, Pierce, Fenner & Smith Incorporated 
 One Bryant Park 

New York, NY 10036 
 As representatives of the
several Initial Purchasers 
 Re: National Financial Partners Corp. - Lock-Up Agreement 

Ladies and Gentlemen: 
 The
undersigned understands that you, as representatives of the initial purchasers (the “Representatives”), propose to enter into a Purchase Agreement on behalf of the several Initial Purchasers named in Schedule I to such agreement
(collectively, the “Initial Purchasers”), with National Financial Partners Corp., a Delaware corporation (the “Company”), providing for the sale of the Company’s Senior Convertible Notes due 2017 (the “Notes”)
which have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) and are being offered and sold in the United States only to qualified institutional buyers in reliance on Rule 144A under the Securities
Act. 
 In consideration of the agreement by each of the Initial Purchasers to offer and sell the Notes, and of other good and
valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning from the date of the Offering Circular (as defined in the Purchase Agreement) and continuing to and
including the date 90 days after the date of the Offering Circular, the undersigned will not offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of common stock of the Company
(the “Shares”), or any options or warrants to purchase any shares of common stock of the Company, or any securities convertible into, exchangeable for or that represent the right to receive shares of common stock of the Company, whether
now owned or hereinafter acquired, owned directly by the undersigned (including holding as a custodian) or with respect to which the undersigned has beneficial ownership as such term is used in the rules and regulations of the Securities and
Exchange Commission (collectively the “Undersigned’s Shares”); provided, however, in the event the undersigned has restricted stock units vest during the restricted period, the undersigned shall be permitted to have shares withheld by
the Company to satisfy any attendant federal, state, and local tax obligations. 
  

 F-1 

 The foregoing restriction is expressly agreed to preclude the undersigned from engaging in
any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of the Undersigned’s Shares even if such Shares would be disposed of by someone other than the
undersigned. Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to any of the
Undersigned’s Shares or with respect to any security that includes, relates to, or derives any significant part of its value from such Shares. 

Notwithstanding the foregoing, the undersigned may transfer the Undersigned’s Shares (i) to or among the undersigned’s spouse, children,
grandchildren, or other living descendants , or to a trust or family partnership of which there are no principal (i.e. corpus) beneficiaries or partners other than the grantor or one or more of the undersigned, the undersigned’s spouse or
described relatives and, provided in the case of a trust, that existing beneficiaries and/or trustee(s) and/or grantor(s) of such trust have the power to act with respect to the trust’s assets without court approval and, in the case of a family
partnership, that the partners thereof have the power to act with respect to the partnership’s assets without court approval and the partnership is not permitted to (x) distribute assets to persons who are not among the relatives listed
above or (y) have partners who are not among the relatives listed above, (ii) to a legal or personal representative of the undersigned in the event of the undersigned’s death or inability to engage in any substantial gainful activity
by reason of any medically determinable physical or mental impairment which can be expected to be long-continued and of indefinite duration, (iii) pursuant to a qualified domestic order, (iv) to a management company or manager of a
subsidiary of the Company, to any Affiliate (as defined by Rule 405 of the Securities Act) thereof, or to any Principal (as such term is defined in the management agreement between the undersigned and the Company, if any) or other employee of such
management company (v) in the event of the death of the undersigned, upon a determination of the Board of Directors of the Company (the “Board of Directors”) that the provisions of this Lock-Up Agreement result in undue hardship
including, without limitation, because of an obligation to pay estate taxes, subject to terms and conditions as are determined by the Board of Directors, (vi) upon a waiver of the provisions of this Lock-Up Agreement by the Board of Directors
in connection with any business combination, restructuring, recapitalization or other extraordinary transaction that has been approved by a majority of the Board of Directors or (vii) with the prior written consent of Goldman, Sachs &
Co. on behalf of the Initial Purchasers. In addition, notwithstanding the foregoing, if the undersigned is a corporation, the corporation may transfer the capital stock of the Company to any wholly-owned subsidiary of such corporation; provided,
however, that in the case of such a transfer or any other transfer contemplated by clause (i), (ii), (iii), or (iv) above, it shall be a condition to the transfer that the transferee execute an agreement stating that the transferee is
receiving and holding such capital stock subject to the provisions of this Lock-Up Agreement, and there shall be no further transfer of such capital stock except in accordance with this Lock-Up Agreement, and provided further that any such transfer
shall not involve a disposition for value. The undersigned now has, and, except as contemplated by clause (i), (ii), (iii), (iv), (v), (vi) or (vii) above, for the duration of this Lock-Up Agreement will have, good and marketable title to
the Undersigned’s Shares, free and clear of all liens, encumbrances, and claims whatsoever, other than any pledge of such Undersigned’s Shares in favor of the Company in existence on the date hereof. The undersigned also agrees and
consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Undersigned’s Shares except in compliance with the foregoing restrictions. 

 

 F-2 

 The undersigned understands that the Company and the Initial Purchasers are relying upon this Lock-Up
Agreement in proceeding toward consummation of the offering. The undersigned further understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors, and assigns.

  

	
	Very truly yours,
	
	  
  

	Exact Name of Stockholder

  

 F-3 

 Annex I 

Term Sheet 

Dated June 9, 2010 

FINAL PRICING TERMS 

The information in this term sheet supplements National Financial Partners Corp.’s preliminary offering circular, dated June 9, 2010 (the
“Preliminary Offering Circular”), and supersedes the information in the Preliminary Offering Circular to the extent inconsistent with the information in the Preliminary Offering Circular. Terms used in this term sheet but not defined have
the respective meanings given to them in the Preliminary Offering Circular. 
  

			
	The issuer	  	National Financial Partners Corp. (NYSE: NFP).
		
	Securities offered	  	4.0% Convertible Senior Notes due 2017.
		
	Aggregate principal amount offered	  	$125,000,000.
		
	Over-allotment option	  	$15,000,000.
		
	Maturity date	  	June 15, 2017.
		
	Interest	  	4.0 % per annum, accruing from the settlement date.
		
	Interest payment dates	  	Each June 15 and December 15, beginning December 15, 2010.
		
	Price to public	  	100%.
		
	NYSE closing price on June 9, 2010	  	$10.51 per share.
		
	Conversion premium	  	22.50% above reference price.
		
	Conversion rate	  	77.6714 shares of common stock per $1,000 principal amount of notes, subject to adjustment.
		
	Conversion price	  	$12.87 (approximately) per share of common stock, subject to adjustment.
		
	Free convertibility period	  	At the option of the holder, holders may convert their notes, in multiples of $1,000 principal amount, at any time on or after April 15, 2017 through the second scheduled trading
day immediately preceding the maturity date.
		
	Trade date	  	June 10, 2010.
		
	Settlement date	  	June 15, 2010.
		
	CUSIP	  	63607PAB5
		
	Joint book-running managers	  	Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated
		
	Lead manager	  	Wells Fargo Securities, LLC
		
	Co-managers	  	RBS Securities Inc. and U.S. Bancorp Investments, Inc.

  

 F-1 

			
		
	 Method of distribution
	  	Rule 144A
		
	 Use of proceeds
	  	 The net proceeds of the offering are expected to be approximately $120.3 million (or approximately $134.8 million if the initial
purchasers exercise in full their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and the expected expenses of this offering. The issuer intends to apply the net proceeds from this
offering to the following uses:
  
 (i) approximately $12.9 million (and
additional proceeds if the purchasers exercise their over-allotment option in full) to pay the cost of the convertible note hedge transactions (after such cost is partially offset by the proceeds from the warrant transactions); and

 
 (ii) the remaining proceeds, together with borrowings under its proposed new credit
facility, to the extent available, and cash on hand, if necessary, to purchase all existing convertible notes accepted for purchase in its tender offer, to repay all outstanding borrowings under its existing credit facility (if its new credit
facility becomes effective), to pay related fees and expenses and for general corporate purposes, all as more fully described in the Preliminary Offering Circular.

		
	 Capitalization
	  	The following table sets forth NFP’s cash and cash equivalents and consolidated capitalization as of March 31, 2010 on (i) an actual basis and (ii) as adjusted to give effect
to the estimated sources and uses of the transactions described under “Use of Proceeds” in the Preliminary Offering Circular and based on the assumption that the proposed new credit facility becomes effective. To the extent that NFP does
not purchase in the tender offer an amount of its existing convertible notes that is greater than the principal amount of notes sold in this offering, its total debt will be higher as a result of the offering (before taking into account the effects
of ASC 470, as described in footnote (e) below). The following table assumes that the initial purchasers have not exercised their option to purchase additional notes.

 

									
	 	  	As of March 31, 2010	 
	 	  	Actual	 	 	As Adjusted	 
	 	  	(in thousands)	 
	 Cash and cash equivalents
	  	$	50,961	  	 	$	24,438	  
		  	 	 	 	 	 	 	 
	 Long-Term Debt:
	  				 			
	 Existing credit facility(a)
	  	$	35,000	  	 	$	35,000	  
	 Existing convertible notes (b)
	  	 	207,455	  	 	 	—  	  
	 New revolving credit facility (c)
	  	 	—  	  	 	 	—  	  
	 New term loan credit facility (d)
	  	 	—  	  	 	 	125,000	  
	 Notes offered hereby (e)
	  	 	—  	  	 	 	86,087	  
			
	 Stockholders’ equity:
	  				 			
	 Preferred stock, par value $0.01 per share: 200,000 shares authorized; none issued, actual and as adjusted
	  	 	—  	  	 	 	—  	  
	 Common stock, par value $0.10 per share: 180,000 shares authorized; 44,769 issued and 41,926 outstanding, actual and as adjusted

	  	 	4,477	  	 	 	4,477	  
	 Additional paid-in capital (e)
	  	 	879,300	  	 	 	883,609	  
	 Accumulated deficit
	  	 	(432,397	) 	 	 	(429,865	) 
	 Treasury stock, 2,843 shares, and 2,843 shares at cost, actual and as adjusted
	  	 	(102,572	) 	 	 	(102,572	) 
	 Accumulated other comprehensive income
	  	 	140	  	 	 	140	  
		  	 	 	 	 	 	 	 
	 Total stockholders’ equity
	  	 	348,948	  	 	 	355,789	  
		  	 	 	 	 	 	 	 
	 Total capitalization
	  	$	591,403	  	 	$	601,876	  
		  	 	 	 	 	 	 	 

  

	(a)	Comprises amounts outstanding under the existing credit facility. 

  

 F-2 

	(b)	On June 9, 2010, NFP commenced a tender offer to purchase for cash any and all of its outstanding existing convertible notes at $955 for each $1,000 principal
amount of existing convertible notes. The outstanding principal amount of the existing convertible notes is $230 million, the liability component of which is reflected in NFP’s March 31, 2010 balance sheet at $207.5 million in accordance
with ASC 470, which is further described in footnote (e) below. 

	(c)	The proposed new credit facility is expected to be structured as a $100.0 million four-year revolving credit facility and a maximum $125.0 million four-year term loan
facility. NFP currently intends to use the proposed new revolving credit facility primarily for general corporate purposes. 

	(d)	The proposed new term loan facility will be used primarily for the purchase of NFP’s existing convertible notes in accordance with the tender offer.

	(e)	Amounts shown reflect the application of ASC 470, which requires issuers to separately account for the liability and equity components of convertible debt instruments
that allow for net share settlement. In accordance with ASC 470, NFP estimates that $125.0 million of the aggregate principal amount of the notes will be recognized as follows (in thousands): 

 

					
	 Liability component:
	  			
	 Principal
	  	$	125,000	  
	 Less: debt discount
	  	 	(38,913	) 
		  	 	 	 
	 Net carrying amount
	  	$	86,087	  
		  	 	 	 
	 Equity component
	  	$	38,913	  
		  	 	 	 

 The equity component associated with the notes is reflected in the capitalization table as an increase to
additional paid-in capital, as adjusted. Additional paid-in capital, as adjusted, has also been reduced by $12.9 million representing the cost of the convertible note hedge transactions in respect of the notes (after such cost is partially offset by
the proceeds to NFP of the warrant transactions). 
  

			
	Adjustment to conversion rate upon fundamental change	  	The number of additional shares by which the conversion rate will be increased in the event of a fundamental change will be determined by reference to the table below, based on
the date on which the fundamental change occurs or becomes effective (the “effective date”) and the price (the “stock price”) paid per share of the issuer’s common stock in the fundamental change. The stock prices set forth
in the first row of the table below (i.e., the column headers) will be adjusted as of any date on which the conversion rate of the notes is otherwise adjusted. The adjusted stock prices will equal the stock prices applicable immediately prior to
such adjustment, multiplied by a fraction, the numerator of which is the conversion rate immediately prior to the adjustment giving rise to the stock price adjustment and the denominator of which is the conversion rate as so adjusted. The number of
additional shares will be adjusted in the same manner as the conversion rate as set forth under “Description of Notes—Conversion Rate Adjustments” in the Preliminary Offering
Circular.

  

 F-3 

			
		  	The following table sets forth the hypothetical stock prices and the number of additional shares to be received by which the conversion rate for the notes will be increased per
$1,000 principal amount of the notes in the event of a fundamental change:

  

																											
	 	  	Stock Price
	 Effective Date
	  	$10.51	  	$11.00	  	$12.00	  	$12.87	  	$14.00	  	$16.00	  	$18.00	  	$20.00	  	$25.00	  	$30.00	  	$40.00	  	$60.00	  	$80.00
	 June 15, 2010
	  	17.4760	  	17.2693	  	14.7174	  	13.0320	  	11.4278	  	9.6203	  	8.3036	  	7.2959	  	5.4724	  	4.2587	  	2.7770	  	1.3665	  	0.5987
	 June 15, 2011
	  	17.4760	  	16.2440	  	13.6352	  	11.9285	  	10.3205	  	8.5876	  	7.4644	  	6.5469	  	4.9185	  	3.8429	  	2.5204	  	1.2716	  	0.6122
	 June 15, 2012
	  	16.9769	  	15.3189	  	12.5932	  	10.8372	  	9.1879	  	7.4149	  	6.4397	  	5.6230	  	4.2162	  	3.2808	  	2.1322	  	1.0531	  	0.5024
	 June 15, 2013
	  	16.4364	  	14.6516	  	11.7361	  	9.8477	  	8.0900	  	6.2301	  	5.3370	  	4.6480	  	3.4728	  	2.6801	  	1.7116	  	0.8104	  	0.3754
	 June 15, 2014
	  	16.2242	  	14.2447	  	11.0657	  	8.9919	  	7.0746	  	5.0329	  	4.1097	  	3.5874	  	2.6401	  	2.0096	  	1.2326	  	0.5125	  	0.1947
	 June 15, 2015
	  	16.2458	  	14.0055	  	10.3926	  	8.0629	  	5.9112	  	3.7043	  	2.7800	  	2.3962	  	1.7339	  	1.2834	  	0.7242	  	0.1921	  	0.0000
	 June 15, 2016
	  	16.6056	  	13.9101	  	9.6348	  	6.9446	  	4.5402	  	2.2529	  	1.5090	  	1.3033	  	0.9416	  	0.7004	  	0.3990	  	0.1029	  	0.0000
	 June 15, 2017
	  	17.4760	  	13.2377	  	5.6619	  	0.0287	  	0.0000	  	0.0000	  	0.0000	  	0.0000	  	0.0000	  	0.0000	  	0.0000	  	0.0000	  	0.0000

 The exact stock prices and effective
dates may not be set forth in the table above, in which case: 
  

	 	•	 	 If the stock price is between two stock price amounts in the table or the effective date is between two effective dates in the table, the number of
additional shares will be determined by a straight-line interpolation between the number of additional shares set forth for the higher and lower stock price amounts and the two dates, as applicable, based on a 365-day year.

  

	 	•	 	 If the stock price is greater than $80.00 per share, subject to adjustment, no additional shares will be added to the conversion rate.

  

	 	•	 	 If the stock price is less than $10.51 per share, subject to adjustment, no additional shares will be added to the conversion rate.

 Notwithstanding the foregoing, in no event will the total number of shares of common stock issuable upon conversion exceed
95.1474 per $1,000 principal amount of notes, subject to adjustments in the same manner as the conversion rate as set forth under the caption “Description of Notes—Conversion Rate Adjustments” in the Preliminary Offering
Circular. 
  

			
	Purchase of Convertible Note Hedge and Sale of Warrant	  	In connection with the offering of the notes, NFP intends to enter into one or more convertible note hedge transactions with respect to its common stock with one or more of the
initial purchasers (and/or one or more of its/their affiliates) (the “counterparty”). The convertible note hedge transactions will cover, subject to customary anti-dilution adjustments, approximately 9.7 million shares of the issuer’s
common stock. Concurrently with entering into the convertible note hedge transactions, NFP also intends to enter into one or more warrant transactions whereby it will sell to the counterparty warrants to acquire, subject to customary anti-dilution
adjustments, approximately 9.7 million shares of its common stock. If the initial purchasers exercise their option to purchase additional notes, NFP expects to use a portion of the net proceeds from the sale of the additional notes to enter into
additional convertible note hedge transactions. In such event, NFP would also expect to enter into additional warrant transactions.
		
	 NYSE share cap
	  	Certain rules of the New York Stock Exchange potentially limit the number of shares of common stock that an issuer may issue upon conversion of the notes. These standards
generally require an issuer to obtain the approval of its stockholders before entering into certain transactions that potentially result in the issuance of 20% or more of its common stock outstanding at the time the notes are issued unless the
issuer obtains stockholder approval of issuances in excess of such

  

 F-4 

			
		  	limitation. Accordingly, unless NFP has received stockholder approval of such issuances, in the event that the sum of the maximum deliverable shares for each trading day during
the observation period exceeds the NYSE share cap (as defined below), it will not be required to deliver shares or cash with respect to such excess. The “NYSE share cap” is 68.1570 shares per $1,000 principal amount of notes or 60.8544
shares per $1,000 principal amount of notes if the initial purchasers exercise their option to purchase additional notes in full, which is equivalent to 19.99% of the common stock outstanding immediately before the issuance of the notes divided by
the aggregate principal amount of notes outstanding at their initial issuance (expressed in thousands). The NYSE share cap is approximately economically equivalent to the holder of a $1000 principal amount of notes being short 9.5144 call options,
each on one share of common stock, struck at approximately $105.10 or approximately economically equivalent to the holder of a $1000 principal amount of notes being short 16.8170 call options, each on one share of common stock, struck at
approximately $59.46, if the initial purchasers exercise their option to purchase additional notes in full.
		
	General	  	 This communication is intended for the sole use of the person to whom it is provided by the sender.

 
 This communication is being distributed in the United States solely to qualified
institutional buyers, as defined in Rule 144A under the Securities Act of 1933. These securities have not been registered under the Securities Act of 1933, and may only be sold to qualified institutional buyers pursuant to Rule 144A or pursuant to
another applicable exemption.
  
 This material is confidential and is for
your information only and is not intended to be used by anyone other than you. This information does not purport to be a complete description of these securities or the offering. Please refer to the offering circular for a complete
description.
  
 This communication does not constitute an offer to sell or
the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.

Before you invest, you should read the offering circular and the documents incorporated by reference therein that the issuer has filed with the SEC
for more complete information about the issuer and the offering. You may get the incorporated documents the issuer has filed with the SEC for free by visiting EDGAR on the SEC website at www.sec.gov. A copy of the issuer’s offering
circular in connection with the sale of the notes may be obtained from Goldman, Sachs & Co., Attn: Prospectus Depart., 85 Broad Street, New York, NY 10004, Fax: 212-902-9316 or email at prospectus-ny@ny.email.gs.com or from Merrill
Lynch, Pierce, Fenner & Smith Incorporated toll free at 866-500-5408. 
 ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE
NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM. 

 

 F-5 

 Annex I 

ANNEX II(a) 

Comfort Letter 
  

 F-1 

 ANNEX II(b) 

Draft of Bring-Down Comfort Letter 
  

 F-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]